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ABSTRACT

Krisenko, Mariya Ph.D., Purdue University, May 2015. Role of Syk in the
regulation of cytoskeleton and stress granules in breast cancer. Major professor:
Robert L. Geahlen.

The Syk protein-tyrosine kinase, a well-characterized modulator of
immune recognition receptor signaling, also plays important, but poorly
characterized, roles in tumor progression, acting as an inhibitor of cellular motility
and metastasis in highly invasive cancer cells. Multiharmonic atomic force
microscopy (AFM) was used to map nanomechanical properties of live MDA-MB231 breast cancer cells either lacking or expressing Syk. The expression of Syk
dramatically altered the cellular topography, reduced cell height, increased
elasticity, increased viscosity, and allowed visualization of a more substantial
microtubule network. The microtubules of Syk-expressing cells were more stable
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to nocodazole-induced depolymerization and were more highly acetylated than
those of Syk-deficient cells. Silencing of MAP1B, a major substrate for Syk in
MDA-MB-231 cells, attenuated Syk-dependent microtubule stability and reversed
much of the effect of Syk on cellular topography, stiffness, and viscosity. This
study illustrates the use of multiharmonic AFM both to quantitatively map the
local nanomechanical properties of living cells and to identify the underlying
mechanisms by which these properties are modulated by signal transduction
machinery.
Proteomic analyses of Syk-binding proteins identified several interacting
partners also found to be recruited to stress granules. Treatment of cells with
inducers of stress granule formation leads to the recruitment of Syk to these
protein-RNA complexes. This recruitment requires the phosphorylation of Syk on
tyrosine and results in the phosphorylation of proteins at or near the stress
granule. Grb7 is identified as a Syk-binding protein involved in the recruitment of
Syk to the stress granule. This recruitment promotes the formation of
autophagosomes and the clearance of stress granules from the cell once the
stress is relieved, enhancing the ability of cells to survive the stress stimulus.
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CHAPTER 1. INTRODUCTION

1.1 Syk
Thirty-six

years

have

passed

since

the

discovery

of

tyrosine

phosphorylation. It has emerged as a fundamentally important mechanism of
how cells communicate with each other and their surroundings. This discovery
has led to our understanding today of the tyrosine kinome, which represents1015% of the total protein kinase genes in humans, yet plays a major role in many
disease states including cancer.1,2 Our laboratory has contributed to the tyrosine
kinome through the discovery of Syk (spleen tyrosine kinase), which we isolated
from bovine thymus while another group isolated it shortly thereafter from porcine
spleen.3,4 The Syk family consists of only two proteins, Syk and zeta-chainassociated protein of 70 kDa (ZAP-70). Syk is crucial for B development and
immune receptor function particularly during B cell receptor engagement, while
ZAP-70 has an important role in T cell development and function.5-9
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Syk is 72 kDa non-receptor tyrosine kinase consisting of two Src
homology 2 (SH2) domains separated by linker A, while linker B separates the
SH2 domains from the catalytic domain (Figure1.1). Classical activation of Syk is
achieved either by recruitment to immune recognition receptors through its two
SH2 domains, which dock with phosphorylated immunoreceptor tyrosine-based
activation motifs (ITAMs) that contain the consensus sequence YxxI/Lx6-12YxxI/L
located on the receptor, or by phosphorylation on tyrosine.10-12 Phosphorylation
of several tyrosines throughout the kinase not only tunes its activity, but also
impacts its localization to various cytoplasmic structures and organelles.
Phosphorylation on tyrosine 130 releases Syk from ITAM-bearing receptors and
recruits Syk to other locations, including the centrosome where it phosphorylates
a number of centrosomal proteins.13,14 Phosphorylation on tyrosine 317 inhibits
Syk’s activity by promoting its interaction with the ubiquitin ligase c-Cbl.15-19
Phosphorylation within the linker B region on tyrosines 324 and 346 promotes
protein-protein interactions involving many proteins including PLC-, Vav-1, Vav2, and Grb2.20-21 These proteins can bind to one or both phosphotyrosines. We
also have observed Syk’s interaction with Grb7, an adaptor protein, via these two
tyrosine residues (see Chapter 5). Tyrosines 519 and 520 are found within the
activation loop of the catalytic domain. Both tyrosines are phosphorylated in vitro
and in B cells when the BCR is engaged.20-21 Mutations to phenylalanine on both
residues have little effect on the catalytic activity.22 This could be due to the
orientation of them within the active site. This orientation may still allow ATP to
have access. There are three C-terminal tyrosines of Syk (Y623, Y624, and
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Y625). They are phosphorylated at relatively low initial rates.20-21 It is thought
that these tyrosines can provide docking sites for “signalosomes” to be built on.
For example, Y624 is surrounded by pYYDV residues that resemble a binding
site for SH2 domain of adaptor protein of the SLP-family including BLNK/SLP65.23 Formation of this protein complex yields activation of PLC2 that activated
inositol triphosphate and diacylglycerol resulting in protein kinase C activation
and leading to a sustained calcium influx.

1.2 The role of Syk in tumorigenesis
A role for Syk in non-hematopoietic epithelial cells is emerging, particularly
in carcinomas where Syk has a convoluted role of being either a tumor
suppressor in some cells or a tumor promoter in others.24-29 A review of Syk and
its association with tumorigenesis has been published30 and is provided in
Chapter 2.
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1.3 Efforts to understand Syk’s dual role in tumorigenesis
In an effort to understand the dual role of Syk in tumorigenesis, we

conducted a mass spectrometry analysis to identify substrates and interacting
proteins. The identified proteins helped up to identify candidate pathways for the
dual roles. We identified a number of proteins that are linked to motility and
stabilization of cellular cytoskeleton. This pathway supported the hypothesis that
Syk is a tumor suppressor. We also identified a number of proteins involved in
mRNA translation and mRNA sequestration.

These proteins appeared to be

linked to stress granules, which are hypothesized to play a survival role in
cancer.

Interaction of Syk with stress granule machinery supported the

hypothesis that Syk is a tumor promoter through its modulation of cellular
survival. In the next sections I will address each of the candidate pathways:
motility and survival.

1.3.1 Syk as a tumor suppressor negatively effects motility
The effects of Syk on cellular motility and invasion have been extensively
characterized. In breast epithelial cell line, MCF10A, knockdown using shRNA
targeting Syk results in an increase of motility, invasion, and growth in soft
agar.26 It has also been hypothesized Syk can inhibit the transition from epithelial
to mesenchymal phenotype before metastasis occurs.

Comparing gene

expression trends resulting from silencing of Syk expression confirms the loss of
epithelial gene products and the increased expression of genes characteristic of
mesenchymal phenotype.



Syk has been included in the EMT gene core
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signature, and its expression being modulated when EMT-inducing transcription
factors are upregulated.31 It appears that Syk’s catalytically activity is responsible
for its negative motility effects during tumorigenesis. When catalytically inactive
form of Syk was expressed in breast epithelial cell line, MCF7, motility was
enhanced compared to wild-type Syk.32 Similar results were observed in K-Ras
addicted pancreatic carcinomas where the knockdown of Syk expression
resulted in the loss of E-cadherin expression, which is also typically observed
when cells transition to mesenchymal phenotype during EMT.33
One of the substrates that were identified in our mass spectrometry
analysis was MAP1B protein. This protein has been extensively studied in the
regulation of cellular cytoskeleton.

We decided to characterize whether Syk

inhibits motility through the MAP1B pathway.

1.3.2 MAP1B
MAP1-family proteins are microtubule-associated proteins (MAPs) that
bind to the microtubule lattice.34 The family consists of four members: MAP1A,
MAP1B, MAP2, and MAP1S. My research specifically focuses on MAP1B. This
protein is a critical regulator of microtubule dynamics. It is a large protein,
displaying the highest expression in the brain.35 It can either function as a fulllength protein or can be cleaved to form a light and heavy chain.34 The light chain
interacts with stress fibers.36 In our mass spectrometry analysis identified over 17
Syk-dependent phosphorylation sites on MAP1B.

This is intriguing because

many of these tyrosines could regulate MAP1B binding to microtubules, and/or
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association with other proteins to build scaffolds on the microtubules. MAP1B is
primarily known for its influence on microtubule dynamics, enhancing their
assembly rates.34 Its N-terminal microtubule-binding domain associates with
microtubule polymers. It has also been found that MAP1B can modulate the
shape of microtubules by making them longer and more flexible. It is
hypothesized that this could also influence the spatial distribution of microtubules
throughout the cytoplasm.34 Although the majority of the research on MAP1B has
been carried out in neurons, it was shown that MAP1B has the same effect in
fibroblasts.37 It enhanced both the stability of microtubule polymers against
depolymerization agents, and enhanced the acetylation of polymers; a sign of
stable microtubules.

1.3.3 Cytoskeletal networks and motility
Cytoskeletal networks are vital components of cell shape and function.
They are involved in but not limited to important cellular processes including cell
division, differentiation, spatial organization of organelles, sensing extracellular
cues in the environment, migration, and invasion.38 The cytoskeleton is
composed of actin filaments, microtubules, and intermediate filaments. There are
overlapping functions among the three components because they rely on each
other to orchestrate complex changes to the physical properties of cells.38 For
example, although the actin cytoskeleton was first shown to have a significant
role in migration, microtubules also play a significant role. Several studies have
shown that microtubules facilitate focal adhesion turnover specifically during the
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disassembly process.39,40 Without this turnover, cells cannot detach from the
extracellular matrix. For example, MAP4K4 kinase has been shown to regulate
focal adhesion turnover. It interacts with the microtubule polymer and EB2, a
plus-end tracking protein that is found on the tips of growing microtubule
polymers.40 Delivery of MAP4K4 by microtubules is critical for integrin
internalization, which this kinase guides once it is delivered to focal adhesions.40
There are also three well-known GTPases that have been reported to
contribute significantly to motility: Rac1, CDC42, and RhoA.

These proteins

belong to the Ras superfamily. RhoA is involved in the regulation of stress fibers
and focal adhesion turnover.41 Rac1 is involved in membrane ruffling.40 Cdc42
aids in filopodia formation.41 RhoA and Rac1 proteins play antagonistic roles and
there is an intricate crosstalk between the two proteins.

For example, for

lamellipodia formation Rac inhibits Rho.41 Whereas in the lamellum and the rear,
Rho inhibits Rac.41

It has also been shown that Rac1 drives oriented

mesenchymal motility during tumor progression, while RhoA activation is
responsible for amoeboid motility, which many times cells utilize this non-oriented
movement during invasion.41-43
Understanding how each cytoskeletal group contributes individually and
collectively to motility is important because if or when cancer arises, we will
better understand how the cytoskeleton network contributes to the cancer state
and how to target cytoskeletal features that promote carcinogenesis.
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F-actin is composed of G-actin monomers that reversibly polymerize to

form filaments.38 These filaments are thin, flexible fibers approximately 7 nm in
diameter.44 F-actin filaments are organized into bundles forming actin networks.
F-actin filaments are abundant beneath the plasma membrane and provide
mechanical support for the cell.38 Meshwork of F-actin filament bundles play an
important role in the formation and function of lamellipodia during motility. The
actin cytoskeleton at the front of the cell is constantly going through a
treadmilling, which involves polymer depolymerization and then repolymerization.
This allows the membrane to stretch and for lamellipodia to spread as the cell
generates enough force to propel forward.46 Assembly of actin filaments into
stress fibers also helps to reinforce cell morphology.45
Intermediate filaments, as the name implies, have diameters in the range
of 10 nm, falling in between the sizes of actin filaments and microtubules.44
Intermediate filaments are known for their mechanical strength and contributions
to cellular morphology rather than motility. They are composed of hard and soft
keratins compared to actin and microtubules, which are made of monomers
joined together.38,47 Each intermediate filament monomer consists of an alpha
helical rod domain. The dimers are formed when rods coil around each other.47
These dimers stagger together to form tetramers that make up the filament.
These filaments are apolar-having no distinct ends.47 Intermediate filaments are
organized into five groups with expression varying depending on the cell type.
For example, filaments in epithelial cells are largely composed of keratins while
fibroblasts, smooth muscle cells, and white blood cells use vimentin.47
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Microtubules are composed of dimers of alpha and beta tubulin subunits

joined together in a head-to-tail fashion to form hollow pipes approximately 25
nm in diameter.36 Microtubules are the biggest filaments when comparing
filaments’ diameters. They are organized in a polar fashion with the minus-end
located at the microtubule organization center (MTOC) or centrosome.30 This is
where nucleation of microtubule polymers takes place. The plus-end spans out,
and is in dynamic transition between free tubulin heterodimers (shrinkage) and
polymers (growing).30

Microtubules are responsible for many critical cell

functions including motility, intracellular transport, and chromosome segregation
during mitosis.30

1.3.4 Microtubule cytoskeleton and critical proteins involved in cancer cell motility
Motility has an important role in wide-variety of physiological outcomes
including immune surveillance, wound healing, and cancer dissemination.48-52
Typically external cues such as chemotactic gradients initiate and influence the
direction of migration. Migration occurs in a four-step chronological order with
the first two steps overlapping: protrusion, adhesion, contraction, and retraction
(Figure 1.2).53 Initiation of each of these steps requires a significant proportion of
the cytoskeleton to rearrange and eventually efficiently aid cell’s disconnect from
the extracellular environment including basement membrane and cell-cell
contacts. This section will focus on migration in relation to cancer dissemination.
Protrusion is the first step of migration. Once the cell senses the presence
of a chemotactic attractant, polarization towards the extracellular cue is initiated.
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Actin filaments bundle towards the leading edge of the cell forming a protruding
bleb that will become the lamellipodium.45,53 This step also relies on the support
of microtubules.

Studies have shown that cells treated with nocodazole, a

microtubule-destabilizing agent, experience a loss of polarization.54 Microtubules
orient themselves along the horizontal axis of the cell towards the leading edge.
The microtubule organization center (MTOC) reorientation is dependent on the
organization of microtubules.55-57 It is thought that accumulation of dynein motor
proteins on microtubule polymers generates a pulling force to orient the MTOC
toward the protrusion resulting in the MTOC being in front of the nucleus.58
During this stage, microtubules also provide mechanical support by bearing high
compressive loads. Many microtubule-associated proteins and microtubule plusend proteins (+TIPS) contribute to the polarization and maintenance of
microtubule dynamics throughout the formation of lamellipodium. Specifically,
microtubules rely on Rho family proteins.

For example, polymerized

microtubules activate Rac to promote formation of lamellipodia.59 Microtubules
also support trafficking of membrane vesicles, recycling endosomes, delivering
mRNAs to the leading edge to helping to maintain signaling pools there. For
example, in breast cancer there is a significant increase in the expression of Rho
GTPases whose levels are barely detectable in normal mammary tissue.59 In
addition, these proteins are found highly concentrated at the leading edge.53
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While the protrusion phase is occurring, it is necessary for adhesion to

stabilize it. Integrins mediate focal adhesions. Microtubules have been show to
control formation and maturation of focal adhesions and deliver integrins to the
leading edge.60 For example, during hypoxia in MDA-MB-231 cells, Rab11
protein becomes expressed. Rab11 regulates recycling of endosomes of integrin
beta 1 and vesicle transport.61,62 It also has been shown to transport integrin
64 to the plasma membrane.63 In addition, hypoxia promotes an increase in
64 expression that relies on stable microtubules.63 When cells are treated with
the microtubule-destabilizing agent, colchicine, Rab11 trafficking is blocked and
this inhibits focal adhesion turnover.63
Contraction is the third step of migration, which guides the disassembly of
focal adhesions at the rear edge, and it is directly followed by retraction, pushing
the cell forward.53 Microtubules have been shown to be important for these last
two processes. One possible mechanism could be that microtubules contribute
indirectly to contractility through the sequestration of p190RhoGEF and GEFH1.64 These proteins become inactivated when they associate and bind to
microtubules. This interaction promotes initiation of contraction.64 Retraction of
the rear edge is also guided by microtubules. Treatment of cells with low doses
of nocodazole promotes an increase in adhesion to the extracellular matrix.
Microtubules are also needed to release focal adhesions at the rear edge in
order to propel the cell forward.65
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1.3.5 Mechanical properties of cancer cells and detecting changes using AFM
Atomic force microscopy (AFM) is becoming a promising tool to study

cytoskeletal features.

This is particularly useful to the cancer biology field

because during tumor formation while being confined to a restricted space, cells
experience many forces including compression forces and tension forces as they
transition through EMT.67 To adapt to this environment, cancer cells remodel
their cytoskeletal networks. For example, stiffer extracellular matrix from cells
excreting factors into their extracellular environment can induce 5 integrin
production helping the cell to adhere to combat the tension forces applied by a
much stiffer extracellular matrix than what it normally is accustomed to.67,68 Once
the cancer cell metastasizes, cells experience hydrostatic pressure when
circulating through the lymphatic system.66 It is hypothesized that cancer cells
are exposed to different mechanical forces compared to normal cells leading to a
much different mechanical signature that could be distinguished by comparing
cytoskeletal networks between cancer and normal cells.
AFM is a useful technique to study physical properties of substances
because it can provide a mechanical signature of nonliving and living systems
(Figure 1.3).69 This technique uses force measurements by detecting the force
that arises from a probe, called the tip, coming in contact with the sample.69 The
cantilever is attached to the tip and senses any movement changes of the tip as
the tip scans over a sample’s surface. The tip can either come in contact with
the entire surface or tap on various locations on the sample to get a general
representation of the properties of the sample. Typically, the tapping method is
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much better for soft samples compared to scanning.69 AFM can be utilized with
water, buffers, or other media surrounding the sample.69 It also has the ability to
generate 3D surface topographical images in conjunction with light or confocal
microscopy. It can also capture the biophysical properties of samples including
elasticity, adhesion, stiffness, friction, and force-volume measurements.69 A
number of researchers have utilized AFM to study cellular morphology, and it is
becoming much more popular in the cancer biology field.
Cancer research primarily has focused on genetic and biochemical
screening techniques to detect and predict patient outcomes. AFM has slowly
been utilized to supplement and possibly replace current diagnostic strategies.
For example, the mechanical properties of the MCF-10A cell line were compared
to those of the MCF7 cell line. MCF7 cells were less stiff as compared to the
benign MCF10A cell line.70 This change was attributed to a reduction in actin
filaments in the MCF7 cells.70 It was hypothesized that cytoskeletal changes
brought about by the malignant transformation contributed to enhanced migration
and metastasis based on the mechanical signature that was derived.70

In

another study, samples were obtained from pleural effusions of patients with
lung, breast, and pancreatic cancers.

Cancer cells from the effusions were

approximately seventy percent softer than normal cells in the same fluid.71,72 In
another study, AFM was used to record changes in morphology from the
following cell lines exposed to anti-cancer drugs: human cervical carcinoma,
human hepatocellular liver carcinoma, and rat glioma.

Anti-cancer drugs,

colchicine and cytarabine, were used to assess morphological changes in cell
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lines treated with and without these drugs.73 Both of these drugs have been
shown to affect cytoskeletal networks by disrupting microtubule networks.73 In
response to treatment with either drug, the cells displayed an increase in the
fluctuations of the surface components of the cell membrane, an increase in
shrinkage, and/or appearance of pores.73 This example illustrates how AFM can
capture morphological changes and how it can be used to study interactions
between cells and anti-cancer drugs. Changes in the mechanical properties of
cells as they go through the transformation process could be utilized as a useful
biomarker when tracking progression of a particular disease.

1.4. Syk as a tumor promoter
To better understand the functional role of Syk in cancer, we conducted a
series of proteomic analyses to identify substrates and interacting partners.
Among the binding partners we identified several proteins involved in mRNA
metabolism and proteins that are known to associate with SGs, including G3BP,
eIF2, VCP, eIF1A, and HSP70.74,75 These findings raised an interesting question
as to whether Syk also functionally associates with stress granules.

1.4.1 Stress granule composition and formation
Stress granules are cytoplasmic, non-membranous foci consisting of poly
(A) mRNAs and binding proteins, elongation initiation factors, 40S ribosomal
subunits, and other signaling molecules; although their composition can vary
depending on the stress.76 Their formation is temporally regulated, specifically
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being limited to the initiation phase of translation when the mRNA message is still
bound to the 40S ribosomal subunit (Figure 1.3).77 Formation is promoted with
drugs that block translation initiation including puromycin, and inhibited with
drugs such as cycloheximide that block translation elongation.78 Sodium arsenite,
glucose deprivation, proteasomal inhibition, and heat shock are some of the
typical stimuli that promote SG assembly.79-82 These stimuli typically activate the
stress response pathway via phosphorylation of eIF2 on serine residue 51 by
stress-sensing

serine/threonine

kinases

GCN2

(activated

by

glucose

deprivation), HRI (monitors ROS production), PERK (ER stress sensor), and
PKR (activated with viral infections and heat shock).77 Phosphorylation of eIF2
converts it into a competitive antagonist of eIF2B, which promotes the exchange
of GDP for GTP in the eIF2-GTP-tRNAMet ternary complex during translation.77
This depletes the GTP stores of the ternary complex and inhibits translation.
RNA binding proteins TIAR, TIA-1, and G3BP utilize their self-aggregation
domains to promote aggregation and nucleation of factors and thus are
considered an integral part of the formation process.77,83 Overexpression and
phosphorylation of G3BP has also been shown to induce stress granule
formation.77
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1.4.2 Stress granules and chemotherapeutics
Recent evidence suggests that stress granules have an important role in

cancer and neurological diseases making them interesting protein aggregates to
study.76 The role in cancer appears to be through the modulation of prosurvival
pathways.

During the initiation of tumor formation, cells experience many

significant changes in the local environment. This tumor microenvironment and
the response to stress do to changes within the microenvironment are important
to cancer development and the cellular response to chemotherapeutics.

For

example, a number of chemotherapeutic agents have been shown to induce
stress granule formation leading to resistance or apoptosis depending on the
cancer cell and/or therapeutic target. Both Bortezomib (PS341/Velcade), a drug
used to treat mantle cell myeloma and multiple myeloma, and 5-fluorouracil (5FU), a drug used to treat breast, colorectal, head and neck cancer, promote the
formation of stress granules, although by different mechanisms.77,84,85 Treating
colon, cervical, and lung cancer cell lines with Bortezomib induces resistance to
apoptosis via formation of stress granules by activation of HRI kinase pathway.84
To assess whether HRI was responsible for Bortezomib –induced resistance,
HRI was depleted using siRNA directed against HRI. Cells failed to form stress
granules and undergo apoptosis.84 5-FU induces assembly of stress granules via
activation of PKR kinase, and this leads to stress granule assembly.85 Other
cancer treatment methods can induce formation of stress granules but production
of these specific stress granules leads to survival rather than apoptosis. For
example, sodium selenite promotes the production of reactive oxygen species
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(ROS) resulting in ER stress and activation of eIF2 leading to formation of
stress granules in prostate cancer and osteosarcoma cell lines.86 These
particular stress granules are functionally distinct from the canonical ones
because they promote apoptosis rather than survival. Further studies will need
to focus on dissecting the mechanisms by which stress granules either drive cells
to apoptosis or survival.

1.4.3 Stress granules and cancer survival mechanisms
How stress granules modulate prosurvival pathways is still unclear. One
hypothesis is that stress granules selectively regulate the expression of proteins
involved in cell survival by translationally silencing their mRNAs. Another
hypothesis is that they increase local concentration signaling molecules and
potentially deplete the bulk of these molecules in the cytoplasm. Another role for
stress granules is that their formation during stress conditions helps to maintain
effective translation by maintaining proper ratio of mRNA pool in the
cytoplasm.77,87
Several studies have shown that stress granules can inhibit apoptosis and
modulate prosurvival signal transduction cascades through the sequestration and
accumulation of signaling components into insoluble puncta. For example, cells
utilize the mTORC1 complex for growth and survival.88 This complex is
composed of seven core components: mTOR (serine/threonine kinase), raptor
(scaffolding protein), mLST8 (unknown activity), pras40 (inhibitor), deptor
(inhibitor) and tti1/tel2 (scaffolding proteins).88



Oxidative stress can lead to
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mTORC1 activation.88 Formation of stress granules activates an inhibitor of the
mTORC1 complex under stress conditions, astrin, leading to sequestration of the
raptor component of the mTORC1 and its accumulation in stress granules. The
absence of raptor inhibits mTORC1 hyper-activation-induced apoptosis.89 Stress
granule inhibition of apoptosis has also been shown to involve the mitogenactivated protein kinase (MAPK) pathways.90 Environmental stress can trigger
MTK1 activation.

Optimal activation occurs when Rack1 binds to MTK1

producing an inactive pre-formed dimer to which GADD45 binds.

This and

facilitates MTK1 activation leading to an apoptotic response through the p38/JNK
MAPK pathway. Rack1 has been shown to be sequestered into stress granules
resulting in the inhibition of MTK1 and thus downregulation of apoptosis.90 Both
examples support the hypothesis that stress granules are able to sequester
signaling factors, and modulate signal transduction outcomes in the cytoplasm.

1.4.4 Stress granule disassembly and autophagy
Stress granules are dynamic foci varying in protein composition depending
on the type of stimuli they encounter. These foci also range in size and formation
rates. Once a stress stimulus is alleviated, recovery results in the return of bulk
protein synthesis and translation of individual mRNAs resulting in the
disassembly of these microscopically visible puncta. Overexpression of a few
RNA-binding proteins such as Staufen also can promote disassembly.91 Staufen
helps to stabilize the mRNA-polysome interaction, but the mechanism of
clearance is still elusive.91



Another factor that contributes to clearance is
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disruption of protein-protein interactions within the granules.

Grb7 is a well-

characterized adaptor protein that has been shown to be recruited to stress
granules.92 Interestingly, our laboratory has validated Grb7 to be an interacting
partner of Syk. Phosphorylation of Grb7 by focal adhesion kinase (FAK) in stress
granules promotes their disassembly.93

The exact mechanism of disassembly

is still unclear as to whether the aggregates dissolve, break apart, or are
removed/cleared by other cellular machinery.
Recent evidence has suggested autophagy is one of the mechanisms by
which stress granules are cleared. Autophagy is a self-destructive process when
parts of the cytoplasm and intracellular organelles including protein aggregates
are enveloped into autophagocytic vacuoles, called autophagosomes. These
vacuoles can dock and fuse with lysosomes for degradation to take place.94
Autophagy can be induced by a number of different stress stimuli, including
nutrient depletion, ER stress, and pathogen-induced molecular patterns. One
marker of autophagy is microtubule-associated protein 1A/1B-light chain 3 (LC3).
The cytosolic form of LC3 is referred to as LC3-I.

During autophagosome

formation, LC3-I becomes covalently linked to phosphatidylethanolamine, and is
integrated into the autophagosome membrane. When this integration occurs,
LC3 is referred as LC3-II. The level of conversion from LC3-I to LC3-II serves as
as a useful marker for autophagy.95
It has been shown in literature that enhanced autophagy reduces the
number of stress granules in cells.96-99 In one study, Buchan et al. screened
4,249 nonessential gene deletions in yeast and identified mutations that altered
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stress granule assembly. Several of the identified mutations appeared to disrupt
autophagy and this disruption led to an increase in stress granules.98 Valosincontaining protein, VCP, was shown to be a critical component of autophagymediated stress granule clearance.97,98 Knockdown of VCP inhibits stress
granule clearance.

VCP is a critical component of the ubiquitin-dependent

protein quality control system. Upregulation of VCP promotes autophagy and
correlates with poor prognosis of many cancers.

These data support our

observation that during stress granule clearance, Syk-expressing cells clear
stress granules at a faster rate compared to cells that lack Syk. In this system,
we observe an upregulation of autophagy correlated with lower numbers of
stress granules.

Further studies need to be undertaken to investigate how

autophagy and its components degrade stress granules.

1.5 Perspectives
The exact role of Syk in cancer is unclear as its role as a tumor
suppressor or a tumor promoter is context dependent and varies between cancer
cell types.

Even though its role is cancer-type dependent, we do see Syk

displaying a prosurvival role in most cancer types. The biological functions of
Syk arise from its ability to influence down-stream signal transduction pathways
involving cellular proliferation, division, migration, invasion, apoptosis, and
transcription.

In breast cancer, Syk has been shown to display a tumor

suppressor phenotype via inhibition of migration and invasion. In addition, Syk
has been shown to interact with tubulin, the major component of microtubules. It
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would be valuable to understand the underlying mechanisms by which Syk
inhibits motility. In collaboration with Dr. Tao’s laboratory, we performed mass
spectrometry analyses and identified a number of proteins involved in
cytoskeletal stability, particularly microtubule-associated proteins.

To assess

how Syk modulates internal cytoskeletal networks and their influence on
mechanical properties of breast cancer cells, we collaborated with Dr. Raman to
utilize atomic force microscopy to capture Syk-dependent changes in the
physical properties of breast cancer cells. We discovered that Syk promotes
microtubule stability when cells are treated with drugs that promote disassembly
of microtubule polymers. As a result, cells expressing Syk display a different
physical phenotype compared to cells that lack Syk.

For example, Syk

expressing cells are much stiffer and more elastic than are cells lacking Syk. We
identified MAP1B as one of the microtubule-stabilizing proteins through which
Syk functions retain the microtubule architecture when cells are treated with
depolymerizing agents.

It appears that MAP1B is needed to retain a less-

metastatic phenotype.
Our laboratory has recently identified a number of mRNA processing
proteins from mass spectrometric analyses of Syk-binding proteins. One of the
binding proteins is G3BP, a critical component of stress granules.

We

hypothesized that Syk could be recruited to stress granules and as a result
modulate survival of breast cancer cells.

We discovered that Syk utilizes its

linker B region, and is recruited to stress granules via an interaction with Grb7.
At the stress granules, it promotes their clearance by autophagy in a manner
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dependent on its catalytic activity and ability to bind stress granules.
Consequently, Syk promotes the survival of breast cancer cells via enhanced
autophagy in cells in which stress granules have been induced. Together, our
studies indicate that Syk influences many aspects of cellular biology and cancer
biology via cytoskeletal networks and mRNA processing machinery, and this
results in changes in the physiological properties of cells.
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CHAPTER 2. CALLING IN SYK: SYK'S DUAL ROLE AS A TUMOR PROMOTER
AND TUMOR SUPPRESSOR IN CANCER

2.1 Introduction
The autonomous growth of cancer cells is driven by an array of mutations,
amplifications, rearrangements and modifications affecting hundreds of distinct
genes. Only a limited number of these genes express proven, effectively
druggable targets. Prominent among these are protein kinases, important
components of the signal transduction machinery of eukaryotic cells that regulate
the interactions of the cell with its environment and control such processes as
energy metabolism, cell cycle progression, cytoskeletal rearrangement, gene
expression and apoptosis. Tyrosine-protein kinases, which account for 17% of
the human kinome, are particularly attractive drug targets due to their intimate
involvement with the regulation of cell proliferation and survival and their frequent
association with tumorigenesis.1,2 Thus, a number of therapeutic agents targeted
against tyrosine kinases including imatinib (Gleevec) for the inhibition of BCRABL, gefitinib (Iressa) and erlotinib (Tarceva) for targeting activated mutants of
the epidermal growth factor receptor (EGFR) and trastuzumab (Herceptin) for the
inhibition of human epidermal growth factor receptor-2 (HER2) are important
components of the oncologist's armamentarium.1 While a role in malignant
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transformation for many kinases is well documented, the ability of others to
modulate the growth properties of cancer cells is less well understood. SYK
(spleen tyrosine kinase) is a prime example since both tumor promoting and
tumor suppressing roles for this enzyme have been described.
SYK was originally isolated by our group from bovine thymus and by the
Yamamura group from porcine spleen.3-5 These tissue sources are consistent
with expression analyses, which confirm that SYK is expressed at highest levels
in cells of hematopoietic origins.6-8 SYK functions as an essential component of
the signaling machinery of multiple receptors in the immune system that play
important roles in distinguishing self from nonself.9 SYK contains a tandem pair
of SH2 (Src homology 2) domains at the N-terminus that are separated from
each other by a linker A region.10 A longer linker B region separates the SH2
domains from the catalytic domain. Structural analyses indicate that hydrophobic
residues in linker A, linker B and the catalytic domain interact to restrict SYK to a
largely autoinhibited conformation.11 SYK is activated when it is recruited to an
immune recognition receptor through the binding of its SH2 domains to a doubly
phosphorylated immunoreceptor tyrosine-based activation motif or ITAM, a
sequence of amino acids found on most SYK-coupled receptors.12 ITAMs consist
of two sets of YXXL/I sequences separated by 6–10 amino acids. Examples of
receptors possessing ITAM-containing components include the B cell receptor for
antigen (BCR); receptors for IgE (FcRI), IgG (FcRIIa) and IgA (FcRI), the
collagen receptor of platelets (GPVI) as well as NK cell activating receptors and
integrins that signal through associated DAP12 or FcR components.
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Following receptor engagement and clustering, a member of the Src-family of
tyrosine kinases catalyzes the phosphorylation of the more N-terminal tyrosine
within the ITAM to initiate the recruitment of SYK to the receptor.9-13
Phosphorylation of the second ITAM tyrosine, likely by SYK, completes the
formation of the receptor-SYK complex. Binding to dually phosphorylated ITAMs
relieves autoinhibition to activate SYK, which then catalyzes the phosphorylation
of protein substrates primarily on tyrosines located in sites rich with acidic amino
acids (however, recent evidence has shown that SYK also has the ability to
phosphorylate some proteins on serine).11,13-15 SYK itself has multiple tyrosines
that become phosphorylated that regulate its activity and its ability to participate
in

protein–protein

interactions.13

Substrates

for

SYK

consist

of

adaptor/scaffolding proteins such as BLNK, SLP76 and LAT, and multiple
regulatory enzymes that include lipid kinases, phospholipases and guanine
nucleotide exchange factors.9,13

These phosphorylations serve to couple

liganded receptors to the activation of signaling cascades that include the
PI3K/AKT/mTOR, Ras/ERK, PLC/NFAT, and IKK/NFB pathways. These, in
turn, are important modulators of metabolism and gene transcription that
determine the physiological responses of an immune cell to receptor
engagement. The critical involvement of SYK in the activation of immune cells
has made it a popular target for anti-inflammatory therapeutics directed against
such diseases as allergic asthma, rheumatoid arthritis, lupus erythematosus and
thrombocytopenic purpura.16
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In addition to SYK's presence in most hematopoietic cells, there are

multiple reports of SYK in various cell types outside of the immune system,
particularly in epithelial cells from a variety of organs where it is present generally
at much lower levels.6-8,17,18 For example, SYK is present in epithelial cells of the
breast at levels at least 6-fold lower than in infiltrating immune cells.19 However,
Syk haploinsufficient mice exhibit increased ductal outgrowth, suggesting an
important role for SYK in tissue homeostasis in the breast.20 There also are many
examples of individual cell lines that are not of hematopoietic origin that have
levels of SYK mRNA as high as or even higher than those found in lymphoid cell
lines.8

2.2 SYK as a tumor promoter
2.2.1. SYK and cell survival signaling downstream of the BCR in hematopoietic
malignancies
Much of the attention on SYK as a promoter of cancer cell growth has
focused on malignancies of B cell origins and the role of tonic or chronic
signaling from the BCR in the maintenance of tumor cell viability. During the
course of B cell development in the bone marrow, successful rearrangement of
the immunoglobulin heavy chain locus yields a pre-B cell receptor that contains
the heavy chain, surrogate light chains and an associated heterodimer of CD79a
and CD79b, which are the signaling subunits that contain the ITAM sequences.21
Successful gene rearrangement and receptor assembly are required for cells to
survive the pro- to pre-B cell transition through signals sent from the pre-BCR via
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SYK. Consequently, SYK-deficient B cell precursors largely fail to progress to the
pre-B cell stage of development.22 Those that do make the transition, mainly
through the expression of low levels of the SYK family kinase, ZAP-70, fail to
progress further to become mature B cells.23 This latter transition requires
rearrangement of the light chain locus and the production and expression at the
cell surface of a mature B cell receptor, again associated with the CD79a and
CD79b signaling components. At this stage of development, SYK is again
required for cell survival and is thought to be activated by tonic signaling (i.e.,
signaling in the absence of antigen) from the assembled BCR complex.21 In fact,
sustained BCR expression and tonic signaling are required for the continued
survival of mature B cells.24 Signaling through the BAFF (B cell-activating factor)
receptor, a tumor necrosis factor (TNF)-family receptor required for follicular B
cell survival, also co-opts SYK, the BCR and its ITAMs as part of its mechanism
to promote cell survival.25
In a mouse model of non-Hodgkin lymphoma, mice bearing both a c-Myc
oncogene driven by an immunoglobulin enhancer (Eμ-MYC) and a HEL specific
BCR (BCRHEL) develop lymphoid tumors that are reliant on tonic BCR signaling
for survival.26 Further introduction of a soluble hen egg lysozyme transgene to
generate an Eμ-MYC/BCRHEL/sHEL mouse results in the appearance of more
aggressive tumors that are chronically activated through the BCR and resemble
Burkitt's lymphoma.
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This supports the concept that either tonic or chronic signaling through the BCR
contributes to tumorigenesis. In both tumor types, the silencing of SYK
expression induces apoptosis and inhibits tumor formation in mice.
A prime example of a role for SYK and the BCR in tumorigenesis is B cell
chronic lymphocytic leukemia (B-CLL). B-CLL arises due to the clonal expansion
of phenotypically mature B cells. B-CLL cells are typically BCR positive and fall
into two general classes: an indolent form with mutated immunoglobulin variable
heavy chain region (IgVH) genes and a clinically aggressive form with unmutated
IgVH genes that also express the SYK-family kinase, ZAP-70.27 ZAP-70 is not
normally found in B cells and its ability to enhance tumorigenesis in B-CLL does
not require it to be catalytically active, suggesting a scaffolding function for the
enzyme.28 Cells of both classes are characterized by the presence of elevated
levels of constitutively active SYK.29 Whether SYK activation occurs due to BCR
engagement by an unknown antigen through chronic signaling—the IgM
repertoire of B-CLL samples is less polymorphic than one would expect from
random gene rearrangements—or from ligand-independent tonic signaling from
the assembled BCR complex is not completely clear, although either mechanism
may drive tumor development.30
The inhibition of SYK activity or the silencing of SYK expression in both
indolent and aggressive B-CLL triggers apoptosis by the conventional
mitochondrial/caspase 3 pathway.29,31,32 The highly malignant, unmutated class
of cells is particularly dependent on the activity of SYK for survival.31 In a phase
1/2 clinical trial of the SYK inhibitor fostamatinib, 55% of human patients with B-
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CLL had a positive response to therapy.33 Cells from treated patients exhibited a
reduced profile of BCR-mediated activation events including decreased
expression of NF-B and c-Myc target genes, reduced activation of BTK (a
tyrosine kinase activated down stream of SYK), lowered levels of MYC and
JUNB, and decreased expression of cell surface activation markers, all
consistent with an inhibition of BCR signaling.34
BCR-dependent signaling also is involved in diffuse large B cell lymphoma
(DLBCL). DLBCL is a heterogeneous collection of malignancies, a subset of
which are BCR positive, display gene expression signatures consistent with antiIgM-activated B cells and are reliant for survival on the expression of
components of the BCR complex.35 Many DLBCL cell lines exhibit tonic or
chronic signaling from the BCR that results in the constitutive phosphorylation of
SYK on activation loop tyrosines.36 An evaluation of 61 DLBCL tumor samples
from human patients found that 44% had elevated levels of phosphorylated SYK;
and this phosphorylated SYK was localized to the plasma membrane where BCR
complexes are found.37 A fraction of primary DLBCL samples exhibit increases in
SYK gene copy number, which correlates with increased protein expression.
BCR-dependent DLBCL cells also frequently overexpress the transcriptional
repressor, BCL6, which down regulates the expression of PTPROt, a receptortype protein tyrosine phosphatase and negative regulator of SYK-dependent
BCR signaling.39 Thus, a decrease in PTPROt expression enhances tonic
signaling from the BCR.40 The SYK inhibitors R406 and PRT318 are cytotoxic or
cytostatic for most BCR-positive DLBCL cells.36,37 The knockdown of SYK by
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siRNA arrests cell cycle progression in PRT318- sensitive DLBCL cell lines,
which phenocopies the effects of the SYK inhibitor.37 Consistent with these
observations, a positive response rate of 22% for DLBCL patients was observed
in a clinical trial of fostamatinib.33
The constitutive activation of SYK also has been reported in other B cellderived malignancies including follicular lymphoma (FL), mantle cell lymphoma
(MCL) and marginal zone lymphoma (MZL).41-43 Primary FL cells are
hyperresponsive to BCR engagement as compared to tumor-infiltrating, but
nonmalignant B cells.44 In MCL, a rare but deadly form of non-Hodgkin
lymphoma, SYK is frequently overexpressed due to gene amplifications in both
cell lines and primary tumor samples.42 In splenic MZL, SYK expression also is
upregulated, potentially due to the downregulation of miR-27b and miR-377
microRNAs, which are predicted to modulate SYK gene transcription.43,45 In both
FL and MCL, the SYK inhibitor, piceatannol, is toxic to cells expressing
constitutively active, phosphorylated SYK. In summary, the accumulating
evidence indicates that SYK is clearly an important mediator of tonic and chronic
signaling through the BCR in multiple B cell-derived lymphomas where it plays a
major role to support cell survival.
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2.2.2 SYK and cell survival signaling downstream of receptors other than the
BCR in hematopoietic malignancies
A role for SYK in supporting tumor cell growth is not restricted to cells

expressing ITAM-containing components of the BCR complex. In B cell acute
lymphocytic leukemia (B-ALL) a large percentage of malignant cells are derived
from pro-B cells that lack pre-BCR or BCR complexes. However, these tumor
cells survive and develop many characteristics of pre-B cells even in the absence
of the pre-BCR.46 Interestingly, most B-ALL cells and primary isolates from
patients still have elevated levels of constitutively active, phosphorylated SYK
and their growth both in culture and in tumor xenografts is attenuated by
inhibitors of SYK activity.46-48 The expression of SYK can be detected in 94% of
peripheral T cell lymphomas (PTCLs) and immunoblotting experiments indicate
that the kinase is constitutively phosphorylated in these cells.49 The signals that
act upstream of SYK to enhance its activity in B-ALL and PTCL remain to be
identified, although the T cell antigen receptor (TCR) is a clear suspect in
PTCL.50
In some lymphoid cancers, ITAM-containing proteins other than
components of the BCR-signaling complex support the activation of SYK to
promote cancer cell survival. During the latent stage of infection, Epstein–Barr
virus (EBV) expresses the integral membrane protein LMP2A.51 LMP2A interacts
with both Lyn and SYK, the latter through an N-terminal ITAM that, when
phosphorylated, stably associates with SYK's tandem pair of SH2 domains.
These interactions inhibit signaling through the BCR and prevent lytic replication.
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Interestingly, LMP2A serves as a surrogate BCR to promote B cell differentiation
even in the absence of cell surface immunoglobulins by providing the tonic
signals required for B cell survival.52 Thus, B cells expressingLMP2A can
populate lymphoid organs even in Rag-1-deficient mice. While EBV infections are
nearly universal in adults, these are effectively controlled by a cytotoxic T cell
response. However, EBV infections uncontrolled by adaptive immune responses
in immunocompromised individuals can result in EBV+ post-transplant
lymphoproliferative disorder (PTLD). The resulting mainly B cell-derived
lymphomas are characterized by the appearance of constitutively active SYK.53
Most are dependent on SYK expression and activity for survival as both siRNAs
directed against SYK mRNA and the SYK inhibitor R406 induce apoptosis in
these cells.
In acute myeloid leukemia (AML), integrins can function upstream of SYK
to enhance its activity and support tumor cell growth. AML arises from the
enhanced proliferation and defective differentiation of progenitor cells of the
myeloid lineage and thus does not typically express components of the BCR
complex. An investigation of the sensitivity of AML cells to inhibitors of EGFR
(which is not expressed in AML), coupled with a siRNA screen, identified SYK as
a key player in AML pathogenesis.54 Both siRNAs and inhibitors targeting SYK
decrease proliferation and induce differentiation of AML cell lines and primary
AML blasts and inhibit the growth of AML xenografts in mice.54 One clue to the
upstream activator of SYK in AML came from a shRNA-based screen that
identified 3-integrin (ITGB3) as an important factor supporting the proliferation
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and inhibiting the differentiation of AML.55 Downregulation of ITGB3 expression
by RNA interference decreases the level of phosphorylated and activated SYK
and mimics the effects of SYK inhibitors on AML proliferation and differentiation.
Another clue came from a mass spectrometric-based analysis of SYK interacting
proteins in AML cells that identified Mac-2 (2Mintegrin) and FcRI as key SYKbinding partners.56 The engagement of either receptor is coupled to the activation
of SYK. Interestingly, the knockdown of CD18 (2-integrin) or of the FcR chain
attenuates the SYK dependent proliferation of AML cell lines. In both neutrophils
and macrophages, the integrin-mediated activation of SYK requires the
expression of either DAP12 or FcR (FCER1G), both of which contain ITAM
sequences that, when phosphorylated, associate with SYK. The constitutive
phosphorylation of the FcR ITAM and its association with SYK were observed in
AML cells, suggesting its role in the tonic activation of SYK.56,57
Approximately 1/3 of patients with AML have mutations in the FLT3 gene
that result in the expression of a constitutively active receptor tyrosine kinase. In
these cells, a role for SYK also has been implicated.58 Active, phosphorylated
FLT3 physically associates with SYK through its more C-terminal SH2 domain
and SYK, in turn, enhances the activity of FLT3 by phosphorylation. This
cooperative activation of both kinases leads to an increase in the expression of
MYC and MYC target genes.
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2.2.3 SYK fusion proteins in hematopoietic malignancies
An alternative way to generate tonic, SYK-dependent signals is through

gene rearrangements and the production of constitutively active fusion proteins.
Data generated from next generation sequencing indicates that SYK is rarely
mutated in any type of cancer.59 Thus, point mutations in SYK do not appear to
be important drivers of tumorigenesis. However, chromosomal translocations
involving the SYK gene have been detected and these can result in the
production

of

fusion

proteins

that

promote

myeloproliferative

or

lymphoproliferative diseases. For example, a fusion protein in which the
dimerization domain of the TEL gene product is fused to SYK results in an active
kinase that promotes a myeloproliferative disorder.60 Constitutive activation
requires the TEL oligomerization domain and results in the phosphorylation on
tyrosine of the fusion protein. The oligomerization of TEL-SYK through the TEL
domain likely mimics the activation of SYK that occurs during the clustering of the
receptors with it associates. This stimulates SYK autophosphorylation on sites
that modulate its activity and promote its interactions with downstream effectors
that bear SH2 or functionally related domains.13
A fusion protein that contains the N-terminal Tec and PH homology
domains of the tyrosine kinase ITK fused to most of linker B and the catalytic
domain of SYK is found frequently in nonspecific PTCLs. The resulting fusion
protein is constitutively active and its expression leads to the phosphorylation of
downstream adaptor and effector proteins.61,62 Unlike TEL-SYK, ITK-SYK
expression selectively leads to T cell lymphoproliferative diseases, perhaps due
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to a requirement for the expression of SLP-76, which is critical for ITK-SYK
activation and the subsequent phosphorylation of either SYK or ZAP-70, which
then play important adaptor functions downstream of activated TEL-SYK perhaps
similar to the role played by ZAP-70 in B-CLL.63 Expression of neither the TELSYK nor ITK-SYK fusion protein alone is likely to be sufficient for full B or T cell
transformation as recent mouse models indicate that additional genetic changes
are

required

to

overcome

SYK

induced,

Blimp-1-mediated

terminal

differentiation.64

2.2.4 SYK and ITAM-signaling in non-hematopoietic malignancies
The inappropriate activation of SYK through the abnormal expression of
ITAM-containing proteins can contribute to cell transformation in nonhematopoietic cells. For example, mouse mammary tumor virus (MMTV), which
causes adenocarcinomas in mice, expresses an env gene product that, when
expressed in mammary epithelial cells, induces morphological changes
consistent with transformation.66 The Env protein contains an ITAM sequence
through which it associates with SYK. Env-induced transformation requires the
conventional pair of ITAM tyrosines and is blocked by the SYK inhibitor,
piceatannol. Similarly, the ITAM of LMP2A, which contributes to cancer cell
survival in PTLD, also influences the physical properties of EBV-induced
nasopharyngeal carcinoma cells.67 LMP2A associates with SYK via its ITAM and
enhances motility in a manner dependent on the conserved ITAM tyrosines and
on the expression and activity of SYK. The ectopic expression of LMP2A in
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keratinocytes also promotes cell migration in an ITAM- and SYK-dependent
manner by inducing the translocation of V-integrin to the membrane.68 The gene
for C35 (C17orf37), which is located on the HER2 amplicon, is increased in
expression with HER2 gene amplification in human breast cancer.69 C35 also
has an ITAM and its expression in mammary epithelial cells induces invasive
growth

and

triggers

an

epithelial-to-mesenchymal

transition

(EMT)

as

characterized by a loss of E-cadherin. This activity requires both the C35 ITAM
sequence and SYK. It is interesting that, in many of these same cell types, the
expression of SYK in the absence of ITAM containing effectors like Env, LMP2A
and C35 actually inhibits cell motility and EMT (see below). Thus, these
aberrantly expressed, ITAM containing molecules may sequester SYK away from
its normal interacting partners within the cell in much the same way that LMP2A
expression inhibits BCR signaling in EBV+ B cells. They potentially could localize
active SYK near a particular set of substrates whose phosphorylation alters
cellular growth properties.

2.2.5 SYK and cell survival signaling in non-hematopoietic malignancies
Oncogenic mutations in K-Ras are seen frequently in adenocarcinomas of
the pancreas, lung and colon. A recent analysis compared gene expression
profiles of lung and pancreatic cancer cells dependent on the expression of
oncogenic K-Ras for survival to tumor cells not dependent on K-Ras.70
Interestingly, SYK is the gene most commonly expressed in K-Ras-dependent (or
K-Ras addicted) cells that is missing from K-Ras-independent cells. Accordingly,
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SYK protein levels are relatively high in K-Ras addicted cells. In these cells, the
knockdown of SYK expression or inhibition of SYK activity results in caspase 3
activation and cell death. The expression in many cells of oncogenes like K-Ras
induces apoptosis unless cells acquire additional anti-apoptotic measures.71
Thus, it is likely that the pro-survival activity of SYK protects these cells from KRas-induced apoptosis.
A similar pro-survival role for SYK is seen in retinoblastoma.72 Whole
genome sequencing of retinoblastoma cells reveals no significant mutations in
any oncogenes or tumor suppressor genes other than RB1. However, many
epigenetic changes in gene methylation are observed, including reduced
methylation of the SYK gene promoter. As a consequence, SYK is expressed in
both retinoblastoma orthotopic xenografts and cell lines, but is actually absent
from normal retina. Both the application of SYK inhibitors and knockdown of SYK
expression by shRNA result in a dramatic increase in mitochondrial-based
apoptosis. The addition of a SYK inhibitor to the chemotherapeutic regimen used
to treat retinoblastoma in a mouse model significantly improves outcomes, clearly
suggesting SYK as a promising therapeutic target for the treatment of childhood
retinoblastoma.72 Thus, the expression of SYK can protect cancer cells from the
pro-apoptotic consequences of either the loss of Rb or the expression of
activated K-Ras.
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For many tissues—including brain, colon, kidney and ovary—the levels of

SYK mRNA are, in general, higher in cancerous than in normal tissues,
suggesting possible roles for the kinase in tumorigenesis in many cell types
outside of the immune system.8 In ovarian cancer, for example, the expression
level of SYK increases with tumor grade.73 Tumors of low malignant potential
have lower levels of SYK, intermediate levels are present in grade 1 tumors, and
the highest levels are found in aggressive grade 3 cancer cells. The silencing of
SYK expression markedly inhibits anchorage-independent growth and induces
apoptosis in SYK-expressing ovarian cancer cells. An analysis of genes coexpressed in small cell lung cancer (SCLC) reveals SYK as a potential oncogenic
driver.74 An examination of primary tumor samples found SYK present in 11 of 33
SCLC tissues at levels much higher than those in normal alveolar epithelium.
Also, a large majority of SCLC cell lines overexpress SYK mRNA.75 The silencing
of SYK expression by siRNA decreases cell growth and increases apoptosis in
SYK-positive SCLC cells. Similarly, SYK is frequently found in squamous cell
carcinomas of the head and neck (SCCHN) where its expression enhances cell
migration.76 Interestingly, elevated SYK expression is also observed in SCCHN
patient tissues where it correlates with increased metastases to the lymph nodes
and with a poor patient survival.
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2.2.6 Mechanisms of SYK-dependent survival signaling
A fundamental hallmark of a cancer cell is its ability to resist apoptosis, a

capability enhanced by the expression of Syk (Figure 2.1).77 Signaling through
PI3K and AKT, known mediators of pro-survival signaling, is thought to underlie
SYK's role as a promoter of tumorigenesis in many tumors. In normal B cells,
SYK couples the antigen receptor to the activation of the PI3K/AKT pathway.78,79
The activation of PI3K generates phosphatidylinositol 3,4,5-trisphosphate (PIP3),
a membrane anchor for and activator of the serine/threonine kinase, AKT.
Activation of PI3K and AKT in response to BCR-signaling is essential for the
BCR and SYK-dependent tonic signaling that promotes cell survival in normal B
cells as the death of mature B cells resulting from the induced deletion of the
BCR can be rescued by expression of a constitutively active form of PI3K or by
deletion of PTEN.80
AKT is a pleiotropic kinase that controls survival signaling through the
phosphorylation of multiple downstream substrates that play key roles in
regulating the activity and/or expression of pro- and/or antiapoptotic proteins.
Multiple mechanisms are operative in different tumor cell types. An important
downstream target of pro-survival signaling in B-CLL is MCL-1, an anti-apoptotic
member of the Bcl-2 family of cell death regulatory proteins.81 The silencing
ofMCL-1 by RNA interference leads to cell death, indicating its importance as a
downstream target of survival pathways.82 B-CLL cells in general exhibit a SYK
dependent increase in the basal state of phosphorylation of AKT. Activated AKT
phosphorylates and inhibits glycogen synthase kinase 3 (GSK3), a negative
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regulator of MCL-1 protein stability. GSK3 targets MCL-1 for destruction by
phosphorylating it on Ser-159, which stimulates its ubiquitination by the Fbw7containing Skp1-Cullin-F-box complex (SCF) to trigger subsequent proteasomal
degradation.83 Interestingly, PKC also is a downstream target of activated SYK
in B-CLL cells.29 Active PKC promotes the activation of AKT and also functions
independently of AKT to inactivate GSK3 and stabilize MCL-1. This provides an
alternative mechanism by which the level of MCL-1 can be regulated even in
subsets of B-CLL cells in which AKT is not demonstrably activated. Thus, the
treatment of cells with inhibitors of SYK results in the downregulation of MCL-1 at
the level of protein stability due to an AKT and/or PKC-mediated inhibition of
GSK3. In retinoblastoma, the expression of SYK also protects MCL-1 from
degradation, indicating that this mechanism is likely to be operative in multiple
tumor types.72
Activation of the PI3K/AKT pathway also is an important promoter of cell
survival in DLBCLs, although the consequences of activation vary with tumor
type. In BCR-dependent DLBCLs exhibiting high levels of activated NF-B, the
inhibition of SYK or PI3K attenuates the transcription of NF-B-regulated genes
that include BCL2A1, a gene that codes for an anti-apoptotic member of the
BCL-2 family.38 In contrast, in BCR dependent cells with low levels of NF-B,
BCR signaling represses the expression of HRK, a BH3 domain-only proapoptotic protein.38 Inhibitors of either SYK or PI3K enhance the expression of
HRK, which then promotes apoptosis through its interactions with anti-apoptotic
proteins such as BCL-2 and Bcl-xL.38,84
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The expression of LMP2A in EBV-infected cells promotes cell survival

through the SYK-dependent, constitutive activation of PI3K/AKT, which enhances
the expression of the anti-apoptotic protein, BCL-XL (BCL2L1), and protects
EBV+ Burkitt's lymphoma cells from MYC-induced apoptosis.85,86 In EBV+B cell
lymphomas, the inhibition of SYK also results in the degradation of the caspase 3
inhibitor, XIAP, due to a decrease in the AKT-dependent inhibition of HTRA2, a
protease for which XIAP is a known substrate.52,87
Mammalian target of rapamycin (mTOR) is a serine/threonine kinase and
well known regulator of tumor growth and proliferation that is activated
downstream of the PI3K/AKT pathway.88 In AML, inhibitors or shRNA targeting
SYK suppress the activity of mTOR, which is constitutively active in untreated
cells.89 Combinations of SYK inhibitors with inhibitors of PI3K or mTOR synergize
to induce AML cell differentiation.
Interesting positive feed-forward signals also can be stimulated through
the PI3K/AKT pathway to enhance the efficiency of BCR signaling in some tumor
cells. The BCR-mediated activation of SYK and PI3K/AKT in DLBCLs activates
the transcription factor SREBP, a key regulator of genes required for cholesterol
biosynthesis.38 The resulting increased expression of enzymes of the cholesterol
anabolic pathway elevates plasma membrane cholesterol, which enhances BCRsignaling by promoting receptor clustering within cholesterol rich membrane
microdomains or lipid rafts. Additionally, the SYK-dependent activation of AKT
and consequent inhibition of GSK3 increase the intracellular level of MYC, whose
degradation is enhanced when phosphorylated by GSK3. MYC activates the
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miR17-92

cluster

of

microRNAs,

which

enhance

BCR

signaling

by

downregulating the expression of inhibitory proteins including CD22 and FcRIIb
(FCGR2B).90 Both CD22 and FcRIIb contain within their cytoplasmic tails
immunoreceptor

tyrosine-based

inhibitory

motifs

(ITIMs).

ITIMs,

when

phosphorylated on tyrosine, bind negative regulators of BCR signaling including
the lipid phosphatase SHIP1 and the tyrosine phosphatase SHP-1.91 Thus, either
enhanced expression of MYC or of the miR17-92 cluster reduces the expression
of ITIM-containing proteins to promote the BCR-dependent activation of
downstream signaling effectors that include SYK, PI3K and AKT.
SYK also is tied to pro-survival pathways not directly associated with
increased activity of the PI3K/AKT pathway. In multiple cell types including
DLBCL, Burkitt's lymphoma, and breast carcinoma, an interaction of SYK with
nucleolin (NCL) promotes the binding to NCL of the mRNA coding for the antiapoptotic protein, BCL-XL, but not the alternatively spliced message coding for
the smaller pro-apoptotic protein, BCL-XS.92 This interaction with NCL stabilizes
the BCL-XL transcript from being degraded in response to oxidative or genotoxic
stress. SYK also influences the activity of signal transducer and activator of
transcription (STAT) proteins, transcription factors that are activated through
phosphorylation on tyrosine. Of the many STAT proteins, STAT3 and STAT5 in
particular are key regulators of tumor cell survival.93 Proteomic analyses of SYKinteracting proteins in AML identified both STAT3 and STAT5 as direct binding
partners of SYK.56 Both are constitutively activated and phosphorylated in AML
cells in which tonic signaling and SYK activation are mediated by integrins and
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FcR. The expression of constitutively active forms of STAT3 or STAT5 rescues
AML cells from the anti-proliferative effects of inhibitors of SYK activity or
expression. Similarly, the expression in cells of the TEL-SYK fusion protein
results in the phosphorylation of STAT5, while STAT3 is phosphorylated in both
B-CLL and B-ALL cells through a SYK dependent pathway.31,94,95 Interestingly,
the activation of STATs occurs via pathways independent of Janus kinases
(JAKs), the canonical upstream regulators of STAT activity. Finally, in ovarian
cancer cells, SYK promotes cell survival by inhibiting the expression of C-JUN.
Consequently, apoptosis triggered by a loss of SYK is partially rescued by
inhibitors of JNK, the upstream activator of C-JUN.73

2.3 SYK as a tumor suppressor
2.3.1 SYK and tumor suppression in B-ALL
The vast bulk of the evidence from studies on tumor cells of hematopoietic
origins indicates that the presence of SYK and its activation are important for cell
survival and, as such, promotion of tumor growth with one notable exception. The
abnormal alternative processing of SYK mRNA leads to a dramatic reduction in
SYK expression and activity in childhood CD19+CD10- pro-B cell ALL that likely
arrests cellular maturation at the pro-B cell to pre-pre-B cell transition. This is a
rare example where a loss of SYK contributes to malignant progression in a B
cell-derived cancer.96
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2.3.2 SYK and tumor suppression in carcinomas
Defining a precise role for SYK in carcinomas, cancers derived from

epithelial cells, has been a complicated process. In some cell and tissue types,
SYK appears to be associated with a malignant phenotype as discussed above.
However, for many tumor types, SYK is encountered frequently in well or
moderately differentiated carcinomas, but it is absent from poorly differentiated
and invasive cells. Its knockdown in more well differentiated cancers enhances
invasive growth behaviors while its re-expression in highly malignant cancer cells
retards motility and inhibits metastasis. Thus, SYK is frequently described as a
tumor suppressor in many epithelial cell-derived cancers.
An inverse relationship between SYK expression and tumor progression
was first described by Mueller and co-workers studying a role for the kinase in
mammary carcinogenesis.97 At both the mRNA and protein levels, SYK is
present in normal mammary gland epithelial cells and in breast cancer cells of
low metastatic potential, but is absent from highly invasive, malignant cell lines.
In patient samples, the loss of SYK during tumor development is progressive with
levels of the kinase reduced in ductal carcinoma in situ (DCIS) and lost in
invasive breast cancer.19.98 Distant metastases are more frequently encountered
in breast cancer patients with reduced levels of SYK mRNA.99 The loss of SYK is
a consequence of both the methylation of CpG islands in the SYK promoter and
allelic loss. The SYK promoter is frequently hypermethylated in primary breast
tumors, but unmethylated in adjacent normal breast tissue.100 Heterozygotic loss
of the SYK gene is frequent in invasive ductal carcinoma (IDC) and in DCIS
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located adjacent to IDC. Consequently, Syk haploinsufficient mice exhibit an
increased risk of mammary tumors.20
A similar asymmetric distribution of SYK between well and poorly
differentiated cancer cells is seen in a number of different tumor tissues. SYK is
present in normal ducts and ductules in the pancreas and in well differentiated
malignant ducts, but is lost as pancreatic ductal adenocarcinoma (PDAC) cells
progress through moderately differentiated to poorly differentiated.101 Similarly,
SYK is present in differentiated PDAC cell lines, but is absent from less
differentiated lines. Interestingly, the pancreatic and lung cancer cells dependent
on K-RAS (and SYK) for survival have a more epithelial morphology while KRAS-independent cells that lack SYK have a mesenchymal morphology.70
Decreases in the expression of SYK in more malignant, invasive tumor cells due
to epigenetic silencing are also seen in bladder cancer, colorectal cancer,
melanoma,

gastric

cancer,

nasopharyngeal

cancer,

and

hepatocellular

carcinoma (HCC).102-109 Interestingly, SYK levels are controlled also at the
protein level by CHK1, which is frequently overexpressed in HCC. CHK1
phosphorylates SYK on Ser-295 promoting its ubiquitination and proteasomal
degradation.110
Carcinomas at the primary tumor site generally have an epithelial
morphology, are tightly packed, and are characterized by the expression of Ecadherin located at the sites of fixed cell–cell junctions. The process by which
cancer cells leave the primary tumor to enter the circulation and travel to distant
sites requires a transition to a mesenchymal phenotype characterized by a loss
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of cell polarity, increased motility, and enhanced invasive properties.111 This
epithelial-to-mesenchymal transition (EMT) is crucial for embryogenesis and
organ development, but cancer cells use this process to initiate invasion and
metastasis. Variances in the expression of SYK in poorly versus well or
moderately differentiated tumor cells likely reflect intrinsic effects of the kinase on
the differentiation and physical properties of these cells that include the
regulation of EMT. The expression in immortalized, but nontransformed,
MCF10A breast epithelial cells of a shRNA targeting SYK increases cell motility,
invasion, and growth in soft agar and induces a more fibroblast-like morphology
characteristic of EMT.20 Analysis of changes in gene expression resulting from
the silencing of SYK expression confirms the loss of epithelial gene products and
the increased expression of genes characteristic of mesenchymal cells. Similarly,
a catalytically inactive form of SYK expressed in MCF7 cells acts as a dominant
negative mutant to increase tumorigenesis in a mouse xenografts model.97
Comparable results are observed in K-Ras addicted pancreatic carcinomas
where the knockdown of SYK expression leads to a loss of E-cadherin
expression, a characteristic feature of EMT.70 Interestingly, SYK is included in the
EMT core gene signature as a gene reduced in expression in breast cancer cells
undergoing EMT in response to multiple EMT-inducing transcription factors.112
Thus, SYK is a negative regulator of the EMT process, which likely explains
much of its differential expression in well versus poorly differentiated tumors.
The ability of SYK to enhance and support the growth properties of cells
with an epithelial phenotype likely underlies its growth inhibitory effects when re-
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expressed in more malignant, invasive mesenchymal cells that normally lack
SYK. The re-introduction of SYK into highly invasive breast carcinomas reduces
cell motility, invasive growth and slows tumor growth and inhibits metastases in
animal xenograft models.97,113 Similar reductions in cell migration and invasion
are seen when SYK is re-expressed in SYK-negative hepatocellular carcinoma,
colorectal cancer, melanoma and pancreatic adenocarcinoma.101,103-105,109 Gene
expression analyses of SYK-negative Panc1 cells identified significant changes
in the expression of over 2000 genes resulting from the re-expression of SYK
including genes such as MMP2 that are required for invasive growth. Panc1 cells
in which SYK is re-expressed develop a more differentiated phenotype and have
increased cell–cell interactions, which is consistent with the ability of SYK to
enhance cell–cell interactions in breast cancer cells.101,113 Rapid changes in the
physical properties of cancer cells expressing SYK can be observed upon the
application of inhibitors of the kinase.113 Thus, the negative effect of SYK on the
growth properties of metastatic tumor cells is likely a product both of SYKdependent changes in gene expression and the more direct effects of
phosphorylation of modifiers of cytoskeletal dynamics.114,115 For example, SYK
can catalyze the phosphorylation of cytoskeletal proteins such as -tubulin,
cortactin, E-cadherin, -catenin and MAP1B.113-117 SYK also is recruited to the
centrosome where multiple substrates are located.118,119 It is this ability of SYK to
enhance adhesion and negatively affect motility and invasion that explains its
absence from highly aggressive tumor cells and underlies its classification as a
tumor suppressor in certain tumor cell types.
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As carcinoma cells progress to a more highly invasive phenotype, the

suppression of SYK expression and activity likely requires the upregulation of
additional mechanisms for survival. For example, many K-Ras independent
carcinomas are deficient in PTEN and have high levels of active AKT, which
promotes cell survival. Interestingly, a fraction of primary DLBCL samples exhibit
increases in the SYK gene copy number while a distinct subset exhibits a loss of
PTEN, suggesting that both mechanisms may independently promote cell
survival.38,70

2.3.3 Alternative splicing of SYK
Transcription of the SYK gene gives rise to two alternatively spliced
products: full-length SYK, which is sometimes referred to as Syk(L), and the
shorter gene product SYKB, also referred to as Syk(S). SYKB lacks a stretch of
23 amino acids in linker B, referred to as the linker insert or DEL, and is
intrinsically less active as compared to SYK in coupling the BCR to intracellular
signaling.120,121 Growing evidence indicates that SYK and SYKB have different
effects on the growth properties of cancer cells. SYKB is found, along with SYK,
in many breast cancer cell lines in which the SYK gene is not silenced, but is
missing from normal breast epithelial cells.120 Interestingly, unlike full-length SYK,
the ectopic expression of SYKB in highly invasive breast cancer cells fails to
reduce cell invasiveness.120 Similarly, the expression pattern of SYK versus
SYKB varies in HCC. SYK levels are down-regulated in HCC tumor samples as
compared to normal liver tissue, but SYKB levels are actually higher in HCC.122
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Since the phosphorylation site on SYK for CHK1 is located in the DEL sequence,
elevated levels of CHK1 also lead to the selective loss of the full-length kinase
while not affecting the level of SYKB.110 The re-expression of SYK, but not SYKB
in SYK negative HCC cells inhibits cell growth in vitro and tumor growth and
metastasis in vivo.122 In fact, the expression of SYKB moderately enhances
tumor cell growth and promotes the formation of lung metastases in mice. Of the
two splice isoforms, SYKB is found preferentially in poorly differentiated HCC
cells where its presence correlates with increased features of cells having
undergone EMT. In fact, the expression of SYKB is a significant indicator of poor
prognosis in HCC patients.122 Thus, SYKB lacks the tumor suppressive activities
of SYK, and its expression may actually contribute to a more highly transformed
phenotype.
Even in cells where the overall effect of the elevated expression of SYK
enhances tumorigenesis, differences exist in the properties of the two splice
isoforms. An analysis of alternative splicing and its contributions to tumor cell
survival identified splicing of the SYK transcript as a major contributor to ovarian
cancer cell survival.73 In this system, the induction of SYK promotes cell survival,
while the manipulation of SYK gene splicing to decrease SYK and increase
SYKB induces apoptosis. While the level of expression of SYK selectively
reduces the expression of C-JUN to inhibit apoptosis, SYK-dependent changes
in anchorage-independent growth are more a product of the total level of SYK
isoforms expressed. Interestingly, the treatment of cells with EGF selectively
promotes the expression of the full-length kinase to promote cell survival.
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The differential effects of SYK and SYKB on the properties of cancer cells

are generally attributed to differences in their respective localizations within the
cell. Cellular fractionation and immunofluorescence studies indicate that SYK is
present in both the nucleus and cytoplasm, but SYKB is confined to the
cytoplasm.73,120,122 SYK, but not SYKB, can enter the nucleus where it interacts
with histone deacetylases and the transcription factor Sp1 to repress the
transcription of Sp1 regulated oncogenes such as CCD1 (cyclin D1) and FRA1
(FOSL1). Consistent with such a mechanism, the appearance of SYK in the
nucleus is of positive prognostic significance in gastric cancer.107
The basis of the differential localization of SYK and SYKB is not entirely
clear. The DEL region resembles a bipartite nuclear localization signal (NLS) and
the replacement of basic amino acids within this sequence results in the
exclusion of SYK from the nucleus.120 However, the replacement of Y290 (based
on the murine Syk numbering system) with a phenylalanine has the same effect,
but this change actually converts the DEL into a nuclear export sequence
(NES).124 Attachment of the entire linker B region, but not the DEL sequence, to
a heterologous protein can deliver it into the nucleus.120 However, this activity
maps to a region located near the C-terminal end of the linker, well removed from
the DEL, which is located in the N-terminal one-third of linker B.124 The
localization of full-length SYK itself also is subject to regulation as integrin
clustering, BCR engagement and PKC activation result in a translocation of SYK
out of the nucleus.113,124 Regardless of the mechanism, it is clear that an analysis
of changes in the levels of total SYK plus SYKB mRNA and/or total SYK plus
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SYKB protein (e.g., as measured by immunofluorescence microscopy) can be
misleading when assessing the potential involvement of SYK in modulating the
growth properties of a particular cancer type.

2.4 Conclusions
The ability of SYK to function as either a promoter (Table 2.1) or
suppressor (Table 2.2) of malignant cell growth appears to be highly dependent
on the cell type and its stage of differentiation, the relative levels of the two SYK
isoforms that are expressed, the mechanisms acting upstream of the kinase that
lead to its activation, and the biological role played by the kinase. The expression
of SYK in cancer cells affects their growth properties primarily through three
mechanisms: 1) The presence of SYK promotes cell survival by stabilizing at
both the protein and mRNA level the expression of anti-apoptotic proteins. This
activity underlies many of the tumor promoting activities of the kinase. 2) The
presence of SYK alters gene expression to affect cellular differentiation programs
that regulate EMT. This requires that SYK has the capacity to transit from the
cytoplasm into the nucleus. This activity likely explains the differential expression
of SYK between cancer cells of epithelial versus mesenchymal phenotypes. 3)
As a consequence of its catalytic activity, the presence of SYK alters cytoskeletal
dynamics to affect cell–cell and cell–matrix adhesion and cell motility. This
activity likely underlies many of the tumor suppressive activities of the kinase
when reexpressed in mesenchymal cells. However, the latter two functions of
SYK can be corrupted by the elevated or abnormal expression of molecules
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bearing ITAM sequences that result in the aberrant sequestration and
relocalization of the kinase. This dual role for SYK is likely to be a complicating
factor in the development of SYK inhibitors for therapeutic purposes as it will be
important to know the exact role being played by the kinase in the tumor cells
being targeted.
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Table 2.1 Cancers in which SYK functions as a tumor promoter.
Cancer Type
B-cell lymphocytic
leukemia (B-CLL)
Diffuse large B-cell
lymphoma (DLBCL)
Follicular lymphoma
(FL)
Mantle cell lymphoma
Peripheral T cell
lymphoma
Lung cancer
Retinoblastoma
Ovarian cancer
Small cell lung cancer
Squamous cell
carcinoma of the head
and neck













Observation
Constitutively active SYK

Reference
28,31,32

Inhibition of SYK induces
apoptosis
SYK inhibition induces
apoptosis
Inhibition induces
apoptosis
Constitutively active SYK

36-38

K-Ras dependent cells
Inhibition induces
apoptosis
Inhibition induces
apoptosis
Silencing SYK promotes
apoptosis
Elevated SYK expression
enhances motility

41
42
49,62
68
70
71
72,73
74
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Table 2.2 Cancers in which SYK functions as a tumor suppressor.
Cancer Type
Childhood CD19+CD10pro-B-ALL
Breast cancer

Pancreatic ductal
adenocarcinoma
Bladder cancer
Colorectal cancer
Melanoma
Gastric cancer
Nasopharyngeal cancer
Hepatocellular
carcinoma
Ovarian cancer






Observation
SYK loss leads to
malignancy
Decreased SYK
expression correlates
with invasion, metastasis,
and tumor grade.
Loss of SYK in less
differentiated tumor cells
Decreased expression
Decreased expression
Epigenetic silencing
Decreased expression
Decreased expression
Decreased expression
SYK promotes cell
survival while SYKB
induces apoptosis

Reference
94
20, 95-98

68,69
100
101
103
104,105
106
107
71
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CHAPTER 3. MATERIALS AND METHODS

3.1 Plasmids and DNA constructs
Constructs expressing the following EGFP fusion proteins: wild-type (SykEGFP), kinase dead Syk (Syk-EGFP(K396R)), Syk single-site mutants (SykEGFP(Y342F)

and

EGFP(Y342F/Y346F)),

Syk-EGFP(Y346F)),
and

Syk

double-site

analog-sensitive

mutant
Syk

(Syk(Syk-

EGFP(R428Q/M429L/M442A), also referred to as Syk-AQL-EGFP) were
generated in the EGFP-N2 vector as previously described (insert reference).
The corresponding cDNAs were amplified by PCR and cloned into the pCDHCMV-MCS-EF1-GFP+puro lentiviral vector purchased from SBI (reference #
CD513B-1). These were then packaged into lentiviral particles using HEK293T
cells.

Constructs expressing wild-type Syk and kinase dead Syk were

reconstructed using the T-REXTM system to create a tetracycline (Tet) inducible
system. Grb7 cDNA obtained from the DNASU plasmid repository (plasmid
#FLH213100.01X) was amplified by PCR and cloned into mCherry vector VQ
AD5CMV (ViraQuest) between the EcoR1 and XpaI restriction sites. A vector
coding for Grb7-mCherry(R461M) was generated by site-directed mutagenesis
using the transformer mutagenesis kit (Clontech), forward primer: 5’ TTC CTG
GTC ATG GAG AGT CAG CGG A and reverse primer: 5’ GGG GGT TCC GCT
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GAC TCT CCA TGA CCA G. GST-SH2 domain expression construct of human
Grb7 cloned into the pGEX6P1 vector was obtained from Addgene (vector
reference #46444).1

3.2 Cell culture, shRNA knockdowns, and DNA transfections
Syk-deficient MCF7 breast cancer cells were purchased from BD
Biosciences as previously described (insert reference). MCF7 cells, MDA-MB231, DG75 human B lymphoma cells, and BT549 breast cancer cells were
purchased from the American Type Culture Collection (ATCC). The chicken
DT40 B cell lines and all DT40 knockout mutant cell lines were a generous gift
from Dr. Kurasaki from Tokyo, Japan. The MCF7, BT549, and MDA-MB-231 cell
lines were cultured in DMEM medium supplemented with 10% FBS (Gibco),
0.37% sodium bicarbonate, 100 IU/ml penicillin and 100 μg/ml streptomycin.
DT40 and DG75 cell lines were cultured in RPMI-1640 medium containing 7.5%
FBS, 100 U/ml penicillin, 100 μg/ml streptomycin, and 50 μg/ml 2-ME. Media for
the DT40 cell line was supplemented with 1% chicken serum. Cells were
maintained in a humidified incubator at 37°C with an atmosphere of 5% CO2 and
95% air.
For generation of cells stably expressing Syk-EGFP, Syk-deficient MCF7
cells were infected with lentiviruses, selected in media containing 1 μg/ml
puromycin, expanded and screened for kinase expression by fluorescence
microscopy and Western blotting.
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For Grb7-mCherry expressing cells, MCF7-BD cells stably expressing

Syk-EGFP were transiently transfected with 1 μg of the expression plasmid
encoding Grb7-mCherry or Grb7-mCherry(R461M) using lipofectamine 2000
(Invitrogen). After 24 h, cells were used for experiments.
A MDA-MB-231 cell line with tetracycline-regulated Syk expression was
constructed using the T-REXTM system (Invitrogen) as previously described
(insert reference).2 This cell line was used to generate a line with reduced levels
of MAP1B protein using a set of five TRC small hairpin RNAs (shRNA) that were
individually packaged into lentiviral particles targeting endogenous MAP1B
mRNA (Thermo Scientific). Cells were plated in 10 cm plates at approximately
70% confluence and infected with each sh-RNA-expressing pLKO.1 lentivirus
according to the manufacturer’s instructions. Cells containing integrated lentiviral
sequences were selected using 1 μg/mL puromycin.

Medium containing

puromycin was replaced every 24 h until resistant colonies were observed.
Knockdown of MAP1B was confirmed by immunofluorescence and Western
blotting using antibodies against MAP1B. Two of the five purchased shRNAs
displayed a knockdown phenotype: TRCN 0000226621 and TRCN 000011620.
MDA-MB-231 cells were transiently transfected with 1 μg of each
expression plasmid encoding Syk-EGFP (BD Biosciences), or c-Src (Addgene
plasmid 13663) into cells using lipofectamine 2000 (Invitrogen).
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3.3 Antibodies and other reagents
The

following

antibodies

were

used

for

immunoblotting

and/or

immunofluorescence: Syk (N19, Santa Cruz), acetylated tubulin (T6793, Sigma),
 -tubulin (T5168, Sigma) acetylated lysine (9441, Cell Signaling Technologies),
MAP1B (N-19, Santa Cruz), c-Src (ab47405, Abcam), G3BP (611126,BD
Biosciences), TIAR (D26E4, Cell Signaling Technology), phosphotyrosine (4G10,
Millipore),

Grb7

(A-12,

Santa

Cruz),

LC3A/B

(D3U4C,

Cell

Signaling

Technology), GAPDH (AM4300, Ambion), eIF2 (FL-315, Santa Cruz), phosphoeIF2 (ab32157, AbCam), AlexaFluor 594-conjugated goat anti-mouse IgG
(Invitrogen), and AlexaFluor 405-conjugated goat anti-rabbit IgG secondary
antibodies (Invitrogen).

ProLong Gold Antifade reagent was purchased from

Invitrogen.
Z-Leu-Leu-Leu-al

(MG132)

purchased from Sigma-Aldrich.

and

sodium

arsenite

(NaAsO2)

were

The Src inhibitor 1-(1,1-dimethyllethyl)-3-(4-

methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (PP1) was purchased from
Cayman Chemical. Autophagy inhibitors 3-methyladenine (3-MA) and N2,N4Bis(phenylmethyl)-2,4-quinazolinediamine (DBeQ) were purchased from SigmaAldrich.

Syk-AQL

selective

inhibitors

either

1-(1,1-dimethylethyl)-3-(1-

napthlalenylmethyl)-1H-pyrazolo[3,4-d]pyrimidine-4-amine

(1-NM-PP1)

or

4-

Amino-1-tert-butyl-3-(3-methylbenzyl)pyrazolo[3,4-d]pyrimidine (3-MB-PP1) were
purchased from Cayman Chemical and Calbiochem, respectively.
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3.4 Western blotting
Cells were lysed in 1% NP-40 lysis buffer (50 mM Tris-HCl, pH 7.4, 150

mM NaCl, 1% NP-40, 0.25% sodium deoxycholate, 1 mM EGTA, 10% glycerol,
and protease inhibitor cocktail (65621 AbCam)). The lysates were centrifuged at
14,000 X g for 1 min. Proteins in the supernatant were separated by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and analyzed
by immunoblotting with the indicated antibodies (section 3.3).

3.5 Co-immunoprecipitation
MCF7-BD cells stably expressing Syk-EGFP were lysed in 1% NP-40 lysis
buffer

containing

2

mM

Na3VO4.

Syk-EGFP

tagged

protein

immunoprecipitated using GFP-Trap agarose beads (ChromoTek).

was
Bound

immune complexes were washed with lysis buffer, separated by SDS-PAGE, and
analyzed

by

Western

blotting

with

the

indicated

antibodies.

For

immunoprecipitation of stress granule components, cells were lysed in RNA
stabilization buffer (100 mM KCl, 5 mM MgCl2, 10 mM HEPES pH 7.4, 0.5%
Triton X-100, 100 U/ml RNase inhibitor, 1 mM dithiothreitol, 1 mM
phenylmethylsulfonyl fluoride, and protease inhibitor cocktail). The supernatants
from the lysates were precleared for 30 min by agitation with a mixture of protein
A and G magnetic beads purchased from Thermo Scientific. Cleared lysates
were incubated with the indicated antibodies bound to magnetic beads. Immune
complexes were washed with lysis buffer supplemented with 100 U/ml RNase
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inhibitor, proteins were in the supernatant were separated by SDS-PAGE and
analyzed by Western blotting.

3.6 Grb7 SH2 domain pull down
The GST-SH2 domain of Grb7 was expressed in and isolated from E. coli
by adsorption onto glutathione-agarose.

Immobilized GST-SH2 (~10 μg of

protein) was incubated with lysates of MCF7 cells expressing either Syk-EGFP or
Syk-EGFP(Y342F/Y346F) and then washed extensively with 50 mM Tris-HCl, pH
7.5, 150 mM NaCl, 10% glycerol, and 1% NP-40. Bound proteins were eluted in
SDS-sample buffer and detected by Western blotting.

3.7 Immunofluorescence microscopy
Cells (5x105) cultured on coverslips were fixed with cold methanol for 10 min and
permeabilized with 0.01% Triton X-100 in PBS buffer containing 10% goat
serum. This same buffer was used as blocking buffer. Cells on coverslips were
immunostained with the indicated antibodies. Bound primary antibodies were
detected using an AlexaFlour 594-conjugated goat antimouse IgG secondary
antibody and/or AlexaFluor 405-conjugated goat anti-rabbit IgG secondary
antibody (Invitrogen).

Coverslips were mounted with ProLong Gold Antifade

reagent (Invitrogen) for fluorescence and confocal microscopy.

Slides were

examined by an Olympus BH2-RFCA fluorescence microscope with a 60X
objective equipped with a Sony DXC-950 3CCD color camera and Northern
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Eclipse version 5.0 from Empix Imaging (Mississauga, ON), an EVOS FL
imaging system, and/or a Zeiss LSM 710 confocal microscope.

3.8 Cellular fractionation
For the preparation of cell fractions based on detergent solubility, cells
were lysed in 1% NP-40 lysis buffer.

The detergent-soluble fraction was

separated from the insoluble fraction by centrifugation for 1 min at 18,000 X g.
The insoluble fraction was resuspended in the lysis buffer supplemented with 1%
SDS. Proteins in the supernatants of each fraction were separated by SDSPAGE and analyzed by Western blotting with the indicated antibodies.

3.9 Microtubule stability experiments
MDA-MB-231 cells either expressing or lacking Syk-EGFP or BT549 cells
transfected to overexpress c-Src were cultured on coverslips and treated with 10
μM nocodazole for 30 min. Cells were fixed with cold methanol for 10 min,
permeabilized, blocked, and immunostained with antibody against -tubulin.
Microscopic images generated by fluorescence microscopy of cells that were
immunostained for -tubulin were measured to assess microtubule stability. The
length of the residual microtubule network extending from the nucleus to the
furthest exterior edge of the cell was measured.
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3.10 Stress granule formation and clearance
To induce the formation of stress granules, cells were treated with either

500 μM sodium arsenite for 2 h or 100 μM MG132 (Sigma-Aldrich) for 3 h. For
some experiments, cells were pretreated with 20 nM Src inhibitor PP1 (Cayman
Chemical) for 15 min prior to the induction of stress granule formation.

MCF7-

BD cells stably expressing Syk-AQL-EGFP were selectively inhibited during
stress granule formation or clearance by the addition of either 5 μM 1-NM-PP1
(Cayman Chemical) or 3-MB-PP1 (Calbiochem). For stress granule clearance
assays, MCF7-BD cells stably expressing either wild type or mutant forms of
Syk-EGFP were treated with MG132 for 3 h and then washed with fresh DMEM
media and allowed to recover in fresh media in the absence of the drug for an
additional 4 h. For autophagy experiments, autophagy inhibitors 3-MA (5 mM) or
DBeQ (10 μM) were added during stress granule clearance at the times
indicated.
3.11 Cellular proliferation assay (MTT)
An MTT assay was performed to assess the number of viable MCF7-BD
cells either expressing or lacking Syk-EGFP. Cells were plated into a 96-well
plate 24 h prior to treatment with 1 μM sodium arsenite for 24 h. Thiazolyl Blue
Tetrazolium Bromide (0.5 mg/ml) purchased from Sigma-Aldrich was added for 2
h. Cells were then washed with PBS, and dissolved in DMSO. Absorbance was
measured at 570 nm with background subtraction at 650 nm.
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CHAPTER 4. NANOMECHANICAL PROPERTY MAPS OF BREAST CANCER
CELLS AS DETERMINED BY MULTIHARMONIC ATOMIC FORCE
MICROSCOPY REVEAL SYK-DEPENDENT CHANGES IN MICROTUBULE
STABILITY MEDIATED BY MAP1B

4.1 Introduction
Recent advances in the use of atomic force microscopy (AFM) to record
nanomechanical properties of live cells in liquid media make it possible to map
quantitatively heterogeneous differences in cellular topography, elasticity, and
viscosity at high resolution.1 For example, local property maps of rat fibroblasts
using multiharmonic AFM are sufficiently detailed for visualization of components
and properties of the actin cytoskeleton.1 Unlike conventional quasi-static
techniques in which the bending of the cantilever probe is monitored as a
function of indentation into the cell at each pixel, multiharmonic AFM is a
dynamic AFM method in which the cantilever probe is excited by Lorentz forces
and changes in amplitude, the phase of the oscillator, and other relevant
harmonics are converted into quantitative local property maps.1 This mode works
in the amplitude modulation (AM-AFM) scheme in which the oscillation amplitude
is regulated as the probe scans over the cell. Changes in the physical properties
of cells caused by rearrangements in cytoskeletal networks underlie the ability of
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cancer cells to progress from a static phenotype to a metastatic phenotype.2 This
process is, in turn, controlled by signaling cascades regulated through multiple
effectors, including the protein tyrosine kinase Syk but the mechanisms involved
are poorly understood.3-6 In this study, we examined the utility of multiharmonic
AFM for the characterization of Syk-dependent changes in the physical
properties of cancer cells as a method of both quantifying physical differences in
cells expressing or lacking the kinase and identifying the underlying mechanisms.
Syk is a 72 kDa protein-tyrosine kinase and well-characterized component
of the apparatus required for transducing signals initiated by the activation of
immune recognition receptors in the innate and adaptive immune systems.7,8
While a critical role for Syk in immune cell function is clear, a less familiar role in
the progression of cancer cells of nonhematopoietic origins has become evident.
Syk has been described both as a tumor promoter on the basis of its prosurvival
functions

in

Ras-transformed

pancreatic

and

lung

cancer

cells

and

retinoblastoma and as a tumor suppressor on the basis of its loss from many
highly invasive tumor cells.5,9-17 For example, while Syk is present in relatively
nonaggressive breast cancer cells and cell lines, it is absent from cancer cells
with a highly invasive, metastatic phenotype.10 Reintroduction of the kinase into
malignant breast carcinomas inhibits their motility, invasion, and metastasis.10,18
Similarly, the loss of Syk from relatively noninvasive breast epithelial cells
decreases the number of cellcell junctions, enhances cell motility and invasion,
and promotes the conversion of cells from an epithelial phenotype to a
mesenchymal phenotype.6,18



Changes in the mechanical properties of tumor
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cells that accompany an epithelial to mesenchymal transition (EMT) require
rearrangements in their cytoskeletal networks, involving both microtubules and
microfilaments.2,19,20 In general, cells move through an extension of lamellipodia
at the front of the cell driven primarily by actin polymerization and retraction of
the trailing edge driven by dynamic microtubules that target focal adhesions to
trigger their disassembly.20,21 Thus, dynamic rearrangements in both structural
networks are required for malignant cells to move and metastasize.
Consequently, critical components of malignant transformation and metastasis
include changes in a cell’ s mechanical phenotype, including elasticity, viscosity,
adhesion, and force generation.22,23
To begin to explore Syk-dependent changes in the mechanical properties
of tumor cells, we examined cells expressing or lacking the kinase using AFM to
map the topography and mechanical properties of live cells. Interestingly, we
found that the expression of Syk in highly invasive breast carcinoma cells
dramatically reduced cell height, increased elasticity, increased viscosity, and
allowed visualization of a more substantial microtubule network. Consistent with
these observations, the microtubules of Syk-expressing cells were more stable to
nocodazole-induced depolymerization and were more highly acetylated than
those of Syk-deficient cells. This effect of Syk on microtubule stability, which
required protein phosphorylation, was modulated, in part, through the
microtubule-associated protein, MAP1B, a major substrate for Syk in MDA-MB231 tumor cells.24
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Consequently, down modulation of MAP1B levels in cells attenuated the Syk-

dependent increase in microtubule stability and reversed much of the effect of
Syk expression on the nanomechanical properties of invasive cancer cells.

4.2 Multiharmonic AFM Mapping of Physical Properties of Breast Cancer Cells
Tumor suppressor functions attributed to Syk reflect its ability to inhibit
motility and metastasis when re-expressed in highly invasive cancer cells.10,18
Because the molecular mechanisms underlying this property are poorly
understood, we examined how the expression of Syk would affect the physical
properties of an invasive breast cancer cell line. MDA-MB-231 cells have a
mesenchymal phenotype, are highly motile, and readily form metastases upon
being introduced into mice.36 The expression of exogenous Syk in metastatic
breast cancer cells inhibits their motility and markedly attenuates the formation of
distant metastases.10 We generated a stable line of MDA-MB-231 cells in which
the expression of Syk with a C-terminally enhanced green fluorescent protein tag
(Syk-EGFP) was under the control of a tetracycline-inducible promoter.18 These
cells lack endogenous Syk but, upon being treated with tetracycline, express
Syk-EGFP.
As shown previously, the expression of Syk-EGFP in MDAMB-231 cells
markedly attenuates their motility.18 To begin to explore possible mechanisms by
which Syk influences the properties of MDA-MB-231 cells, we used
multiharmonic AFM to image at high spatiotemporal resolution live cells either
lacking Syk or induced to express Syk-EGFP. In multiharmonic AFM, a
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microcantilever is excited near the natural first flexural frequency, pressed down
against the cell, and scanned across the cell to collect the resulting changes in
the vibration harmonic content, which represents changes in nanomechanical
physical properties of the cells.1 The topography and nanoscale compositional
contrast images [mean cantilever deflection or the zeroth harmonic (A0) and first
harmonic phase lag (1)] for a typical pair of cells are illustrated in Figure 4.1.
Second harmonics were not observed on these cells. The compositional contrast
images of cells lacking Syk (Figure 4.1 AC) exhibit very few cellular features
and no well-defined cytoskeletal organization consistent with the nature of these
cells, which are highly motile with a dynamic internal cytoskeleton. These cells
exhibited a rounded phenotype and were often removed easily from the gelatincoated dish during scanning likely because of their high level of motility and
decreased strength of adhesion. In contrast, the cells expressing Syk-EGFP
were characterized by an increased level of cell spreading (decreased cell
height) and a more organized subsurface cytoskeletal structure (Figure 4.1,
bottom panels). Syk-EGFP-expressing cells also were less likely to evade the
cantilever, because of decreased motility and increased adhesion. The measured
compositional contrast images A0 and 1 were combined to extract the local
nanomechanical properties, specifically the stiff ness and damping of local
Kelvin Voight element ksample and csample.
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ksample is a measurement of the differences in stiffness or rigidity within the cell,
and csample illustrates differences in the damping or cell viscosity (Figure 4.1; a
second example is illustrated in Figure 4.2).1,27 The induction of Syk-EGFP
expression in MDA-MB-231 cells dramatically increased both cell stiffness and
viscosity.

4.3 Effects of Syk on Microtubule Stability
The actin and microtubule cytoskeletons provide the intracellular networks
that determine many of the physical properties of cells.37,38 AFM compositional
contrast images of cells expressing Syk- EGFP revealed subcellular structures
consistent with that of a cytoskeletal network (Figure 4.1, bottom panels). The
size and morphology of this network were more consistent with those of
microtubules than those of actin microfilaments when compared to images of
cells stained with antibodies against -tubulin or labeled with rhodaminephalloidin (Figure 4.3). F-Actin staining was observed primary at the cell cortex,
while microtubule polymers were found throughout the cytoplasm and resembled
the cytoskeletal features revealed by AFM.
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To study in more detail possible effects of Syk on microtubules, we

examined the stability of the microtubule network. MDA-MB-231 cells either
lacking or expressing Syk-EGFP were treated with low concentrations of
nocodazole for 30 min to promote microtubule depolymerization. It has been
shown that differences in the stability of the microtubule network manifest
themselves as changes in resistance to nocodazole-induced depolymerization.39
Cells were fixed and stained with an antibody against -tubulin and examined by
fluorescence microscopy. There was a pronounced difference in the morphology.
of the nocodazole-treated cells between those lacking Syk, in which the
microtubule network was largely disassembled, and those expressing Syk-EGFP,
in which cells retained microtubule structures resistant to drug-induced
depolymerization (Figure 4.4A). To quantify these differences, we determined the
persistence of the microtubule network by measuring the distance of -tubulin
staining from the nucleus to the perimeter of each cell. Results from a
comparison of more than 200 cells are shown in Figure 4.4B. Nocodazole treated
cells expressing Syk-EGFP exhibited a much greater level of retention of tubulin-containing polymers than did cells lacking Syk. In contrast to the
expression of Syk, the overexpression of c-Src, which typically enhances cell
motility, failed to prevent cells from rounding up following treatment with
nocodazole (Figure 4.5).40
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Because MDA-MB-231 cells are somewhat unique among breast cancer

cell lines in that they express activated K-Ras, we also examined the effects of
Syk expression in BT549 human breast carcinoma cells, which do not express
activated K-Ras and also lack endogenous Syk.10 Again, the expression in these
cells of Syk stabilized the microtubule networks and inhibited the rounding up of
cells in response to nocodazole, similar to the results observed for MDA-MB-231
cells (Figure 4.6).
A hallmark of stable microtubules is an increase in their extent of
acetylation on lysine.41

Consequently, we asked if tubulin from Syk-EGFP-

expressing cells was more highly acetylated than tubulin from cells lacking Syk.
MDA-MB-231 cells either not induced or induced to express Syk-EGFP (Figure
4.7A) were lysed in microtubule stabilizing buffer containing 1% NP-40 and
separated by centrifugation into soluble (monomer) and insoluble (polymer)
fractions. Proteins in each fraction were separated by SDS PAGE and analyzed
by Western blotting using an antibody that recognizes lysine-acetylated -tubulin.
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Acetylated tubulin was found predominantly in the polymer fraction as expected
(Figure

4.7B).

Tubulin

from

Syk-EGFP-expressing

cells

contained

an

approximately 3-fold higher level of acetylated lysine, consistent with the
increased stability of the microtubule network in these cells. An increase in the
level of highly acetylated microtubules in the Syk-EGFP expressing cells was
confirmed by immunofluorescence microscopy (Figure 4.8C). When treated with
nocodazole, the Syk-EGFP-expressing cells also retained more lysine-acetylated
microtubule polymers than cells lacking Syk-EGFP. Similar results were
observed in MDA-MB-231 cells transiently transfected to express Syk-EGFP as
compared to Syk-deficient cells (Figure 4.9).

4.4 Role of Phosphorylation in the Stabilization of Microtubules
To determine if Syk-dependent protein phosphorylation was involved in
modulating cytoskeletal dynamics, we asked if the catalytic activity of Syk was
required for the promotion of microtubule stability. We generated a line of MDAMB-231 cells in which the expression of a catalytically inactive version of SykEGFP [Syk-EGFP(K396R)] was under the control of a tetracycline-inducible
promoter. Cells induced to express Syk-EGFP or Syk-EGFP(K396R) were
treated with nocodazole (10 μM) for 30 min, fixed, immunostained with an tubulin antibody, and examined under the fluorescence microscope. There was
an obvious difference in the morphology of drug-treated cells expressing active
versus inactive kinase (Figure 4.10).
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As compared to cells expressing Syk-EGFP, Syk-EGFP(K396R)-expressing cells
were more rounded because of microtubule depolymerization and resembled
cells that lacked Syk. Thus, the ability of Syk to stabilize microtubules was a
function of its catalytic activity.

4.5 Identification of a Syk Substrate Involved in Microtubule Stability
To investigate how active Syk might promote microtubule stability, we
searched for proteins from MDA-MB-231 cells that were both phosphorylated on
tyrosine in a manner dependent on the exogenous expression of Syk and
involved in the stabilization of microtubules. The results of this large-scale
phosphoproteomic analysis of Syk-dependent phosphorylated substrates were
published recently.24
Among the Syk-dependent phosphoproteins identified in our study was
MAP1B, a microtubule-associated protein known to enhance microtubule
stability.41-43 We identified 17 distinct sites of tyrosine phosphorylation on MAP1B
isolated from MDA-MB-231 cells expressing exogenous Syk that were not
phosphorylated in cells lacking the kinase.24

Ten of these sites were also

phosphorylated on MAP1B isolated from DG75 B lymphoma cells, which are
cells that express endogenous Syk at normal levels. Multiple MAP1B derived
phosphopeptides were also identified when tyrosine phosphorylated tryptic
peptides from MDA-MB-231 or DG75 cells were isolated, dephosphorylated in
vitro, and then rephosphorylated by recombinant Syk.44 Many of these sites are
clustered within an area known as the imperfect repeat region (Table 4.1).45,46
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4.6 Effect of the Depletion of MAP1B on Microtubule Stability
To determine if MAP1B was critically involved in microtubule stabilization

in MDA-MB-231 cells, we reduced the level of the protein through RNA
interference. A collection of five different lentiviruses were used individually to
deliver small hairpin RNAs (shRNAs) targeting MAP1B to MDA-MB-231 cells
either expressing or lacking Syk-EGFP. Two of the five shRNAs successfully
reduced the level of MAP1B as measured by the immunofluorescence of infected
and antibiotic-selected cells (an example of one of these is illustrated in Figure
4.11) or by Western blotting (Figure 4.12). To ascertain a role for MAP1B in Sykdependent microtubule stability, we induced the expression of Syk-EGFP in
MDA-MB-231 cells expressing normal or reduced levels of MAP1B. Cells were
treated with nocodazole (10 μM) for 30 min, fixed, and immunostained using an
antibody against -tubulin (Figure 4.13A). The size of the drug-resistant
microtubule cytoskeleton was then measured (Figure 4.13B). Despite the
expression of Syk-EGFP, the MAP1B knockdown cells displayed a morphology
similar to that of cells lacking Syk as cells were more rounded and failed to retain
stable microtubule networks.

4.7 Influence of MAP1B on the Physical Properties of MDA-MB-231 Cells
To investigate roles for Syk in conjunction with MAP1B in modulating the
physical properties of cancer cells, we measured the influence of Syk on the
topography and elasticity of MDA-MB-231 cancer cells in the presence or
absence of normal levels of MAP1B. We estimated elasticity values by AFM
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using the force volume (FV) mode to compare changes in the relative elastic
modulus. In FV imaging, the AFM probe approaches, is pushed against, and is
retracted from the cell surface on a grid of points predefined by the user to record
a resulting force distance curve. Subsequently, the images are processed
offline to extract two quantities of interest: cell height and elasticity. A second
example is shown in Figure 4.14. The respective topography maps are shown in
the top panels and elasticity maps in the bottom panels. The comparative
maximal cell height and elasticity histograms in the nuclear region from multiple
cells are illustrated in panels A and B of Figure 4.15, respectively. The induction
of Syk-EGFP expression in MDA-MB-231 cells dramatically decreased the height
of the average cell from 5.62 ± 1.58 to 3.83 ± 1.26 μm. The cell height was
increased to 4.87 ± 1.22 μm by decreasing the intracellular level of MAP1B in the
Syk-EGFP-expressing cells. Similarly, the expression of Syk-EGFP increased the
cellular elasticity from 0.488 ± 0.199 to 1.35 ± 0.387 kPa. Again, the knockdown
of MAP1B partially reversed this eff ect, reducing the elasticity of Syk-expressing
cells to 0.812 ± 0.224 kPa.
These results indicate that the expression of Syk has pronounced effects
on the physical properties of MDA-MB- 231 cells (decreased height and
increased stiff ness) and that these are mediated in part, but not in full, by the
phosphorylation of MAP1B. Thus, many of the changes in the physical properties
of MDA-MB-231 cells resulting from the expression of Syk are mediated by
alterations in the microtubule cytoskeleton.
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4.8 Discussion
To disseminate from the site of a primary tumor, a cancer cell of epithelial

origin must detach from neighboring cells, migrate from the tumor site,
extravasate into either the vascular or lymphatic systems, travel to a distant site,
extravasate from the circulation, and establish through cell division a new tumor
Mass.3,4,47 To accomplish this, transformed epithelial cells undergo EMT,
whereby they lose E-cadherin-mediated contacts, develop strong cell
extracellular matrix adhesions, and undergo cytoskeletal rearrangements that
allow them to achieve enhanced migratory and invasive properties.48
Considerable work has been done using AFM to measure variations in
mechanical properties as a function of metastatic potential, allowing the detection
of tumor progression. The resulting changes in the mechanical properties of
tumor cells that accompany EMT as measured by AFM include decreased
stiffness, consistent with many observations that cancer cells exhibit an elasticity
significantly decreased in comparison to those of their normal counterparts.38,49
Prior work has shown that metastatic cancer cells are more than 70% softer than
benign cells.50 A decrease in the Young’ s moduli has been reported for prostate
cancer cells with increasing metastatic potential.51 The inhibition or knockdown
of Syk in breast epithelial cells or Ras-dependent pancreatic carcinomas induces
phenotypic changes characteristic of EMT.5,6 Consistent with these observations,
the re-expression of Syk in highly invasive MDA-MB-231 cells, which have a
mesenchymal

phenotype,

substantially

decreases

increases viscosity and the level of adhesion.



cellular

elasticity

and
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The intrinsic stiff ness of cells is a property of cellular cytoskeletal

networks including microtubules and actin microfilaments. The appearance of
subcellular structures resembling microtubules revealed by AFM selectively in
Syk-expressing cells prompted us to explore the effects of the kinase on tubulin
polymers. Microtubules were more stable in Syk-expressing cells as measured
by their insensitivity to drug-induced depolymerization and an increased content
of acetylated lysine, which is a marker of more stable microtubules. Several
studies have demonstrated interactions between Syk and microtubules or
proteins involved in the regulation of microtubule organization. Syk can bind to
and phosphorylate tubulin, and a fraction of the kinase localizes to centrosomes
and associates with a number of centrosomal proteins.44,52,53 The movement of
Syk to the centrosome is dependent on both the catalytic activity of Syk and its
movement along microtubules mediated by the dyneindynactin complex.54 A
phosphoproteomic analysis of Syk-dependent substrates identified several
centrosomal and microtubule-associated proteins.24,44

The substrate with the

most identified sites of phosphorylation was MAP1B, a microtubule-associated
protein found most prominently in the nervous system.55

The expression of

MAP1B in MDA-MB-231 cells was unexpected. However, the abnormal
expression of tissue differentiation markers has been noted previously in many
cancer cells, including MDA-MB-231 and other breast cancer cells.56 We also
detected the phosphorylation of MAP1B on multiple tyrosines in DG75 cells, an
EBV-transformed human B cell lymphoma cell line unrelated to MDA-MB-231.24
On the basis of the Phospho-SitePlus database, phosphotyrosine-containing
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peptides derived from MAP1B also have been identified in a variety of tumor cell
types, including bladder, colorectal, non-small lung, esophageal, Hodgkin’s
lymphoma, and chronic myelogenous leukemia.57
MAP1B is developmentally regulated in the nervous system where it plays
an important role in neurite and axon extension through its ability to bind to
dynamic microtubules in growth cones.43,58-60
MAP1B

in

nonneuronal

cells

stabilizes

The exogenous expression of
microtubules

to

drug-induced

depolymerization and increases the abundance of acetylated microtubules.41,61
When present in MDA-MB-231 cells, these activities of MAP1B are enhanced
considerably by the coexpression of Syk, which phosphorylates the protein on
multiple tyrosines. MAP1B has previously been shown to be extensively
phosphorylated by serine/threonine kinases on a variety of sites spread out
throughout the central region of the molecule.62

Phosphorylation has been

shown to modulate the ability of the protein to bind to and stabilize microtubules
depending on the site or sites that are modified.62 The sites phosphorylated by
Syk are largely clustered within the hydrophilic imperfect repeat region of
MAP1B, a region not directly involved in binding microtubules.46 This region
contains multiple consensus sites of serine phosphorylation for casein kinase 2
(CK2),

which

phosphorylates

MAP1B

and

enhances

its

binding

to

microtubules.63,64 It is reasonable to predict that the phosphorylation of MAP1B
by Syk within this same acidic region would also enhance MAP1B microtubule
interactions, accounting for the ability of Syk to promote microtubule stability.
Interestingly, three of these sites are found within pYXXL/I motifs, which are
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sequences recognized by a subset of SH2 domain-containing proteins, including
Syk itself. Such an interaction may help explain the abundance of tyrosines on
MAP1B that become phosphorylated in cells expressing both MAP1B and Syk.
Because dynamic microtubules play major roles in motility by modulating the
disassembly of focal adhesions and retraction of the trailing edge of migrating
cells, increased stability conferred by the enhanced binding of phosphorylated
MAP1B could reasonably account for many aspects of Syk’ s ability to limit the
motility of highly invasive cancer cells. It is interesting that modulation of the
activity of a microtubule-stabilizing factor produces such dramatic changes in the
mechanical properties of cancer cells as changes in the stiff ness of cells are
most often attributed to alterations in the actin cytoskeleton.38,65,66 However,
there is considerable cross-talk between cytoskeletal systems. For example, Rho
family GTPases, which control actin dynamics, are, in turn, regulated by dynamic
microtubules that interact in a polymerization-dependent fashion with Rho
guanine nucleotide exchange factor 190RhoGEF.67 Thus, dynamic microtubules
are major modulators of the mechanical properties that affect fundamental
processes such as cell adhesion and motility.
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CHAPTER 5. SYK IS RECRUITED TO STRESS GRANULES AND PROMOTES
THEIR CLEARANCE THROUGH AUTOPHAGY

5.1 Introduction
The Syk protein-tyrosine kinase is best known for its many roles in the
adaptive and innate immune systems as a component of the molecular
machinery that couples immune recognition receptors to intracellular signaling
pathways in multiple hematopoietic cell types including B cells, mast cells,
platelets, NK cells, macrophages, and neutrophils.1,2

In these cells, receptor

engagement leads to the phosphorylation of a pair of tyrosines present within
immunoreceptor

tyrosine-based

activation

motifs

(ITAMs)

on

receptor

components, which leads to the recruitment of Syk to the receptor and its
subsequent activation. The participation of Syk in pro-inflammatory signaling
events has led to considerable interest in the use of small molecule Syk inhibitors
for the treatment of diseases such as allergic asthma, rheumatoid arthritis and
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systemic lupus erythematosus.3 The identification of additional roles for Syk in
tumorigenesis has increased interest in the use of Syk inhibitors as
chemotherapeutic agents for the treatment of disorders in which the expression
of Syk serves as a pro-survival factor.4

The inhibition of or knockdown in

expression of Syk promotes apoptosis in multiple cancer cell types including
many hematopoietic malignancies as well as K-Ras-dependent lung and
pancreatic cancer, small cell lung cancer, ovarian cancer and retinoblastoma.5-8
For many cancer cells, the expression of Syk can protect them from cell death
due to genotoxic or oxidative stress.9
Eukaryotic cells respond to external stresses in a variety of ways including
the reprogramming of translational processes.10,11 Insults due to heat shock,
viral infection, oxidative stress, exposure to arsenite, or glucose deprivation
activate kinases that phosphorylate eIF2 to stall translation of mRNAs bound to
initiation complexes and promote polysome disassembly. Messenger RNAs are
rerouted along with their associated proteins into stress granules (SGs), large
ribonucleoprotein (RNP) complexes scaffolded by RNA binding proteins with
glycine-rich self-associating domains. Cytoplasmic poly(A) mRNAs stalled in the
translational initiation phase are sequestered in SGs and potentially protected
from degradation until stress is released and normal protein synthesis can
resume. SGs also can sequester signaling molecules important for apoptosis
and contribute in this fashion to the protection of cells from stress.12,13
The formation of RNP aggregates, however, also can be detrimental to
cell survival.

This is particularly apparent within the nervous system where
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mutations in RNPs that promote self-assembly can be major drivers of
neurodegenerative diseases.14-17 Similarly, defective clearance of SGs leads to
the pathological accumulation of RNP particles.18,19 Genetic studies of regulators
of SG dynamics in yeast identified granulophagy, a form of macroautophagy
(referred to here simply as autophagy), functioning in conjunction with
Cdc48/valosin-containing protein (VCP), as critical for SG clearance.20 Mutations
in VCP are known to cause amyotrophic lateral sclerosis and frontotemporal
dementia, consistent with a role for defects in SG clearance in disease
pathology.18,19 VCP also is upregulated in many human cancers; and tumor cells
use autophagy as a survival strategy when encountering external stresses due to
increased metabolic demands, a challenging microenvironment, or exposure to
therapeutic agents.21-27
To better understand the prosurvival pathways in which Syk functions, we
conducted a series of proteomic analyses to identify substrates and interacting
partners of the kinase.28-30

Among the binding partners we identified were

several with functions in mRNA metabolism that are known to associate with
SGs. This finding raised the interesting possibility that Syk also associates with
SGs and plays a role in SG function or dynamics. In this study, we demonstrate
that Syk is, in fact, recruited to SGs in response to the treatment of cells with
either sodium arsenite or a proteosome inhibitor, both of which are known
inducers of SG formation.31 This recruitment requires the phosphorylation of a
pair of tyrosines on Syk located in a region where the kinase interacts with the
SG component, Grb7. In SGs, Syk is active and catalyzes the phosphorylation of
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proteins on tyrosine. Interestingly, the recruitment of Syk to SGs promotes their
clearance from cells through autophagy and enhances the survival of cells in
which SGs are induced. This previously unknown function of Syk may underlie
many aspects of its ability to promote the survival of cancer cells in the presence
of metabolic or therapeutic stress.

5.2 Syk is recruited to SGs
Previous Syk-dependent substrate and interactive partner screens from
our laboratory identified multiple proteins mapped to specific complexes or
pathways involved in mRNA dynamics.28-30 Specifically, we identified as Sykinteracting proteins an extensive set of SG components including G3BP, a known
scaffolding protein necessary for SG formation (Table 5.1).10,29,37-42 To
investigate a possible direct association of Syk with SGs, we asked whether Syk
was recruited to SGs under conditions that promoted their formation. We treated
a line of MCF7 cells that lacks endogenous Syk (MCF7-BD), but stably
expresses Syk-EGFP, with either the proteosome inhibitor MG132 for 3 hours or
sodium arsenite for 2 hours.34 Cells were fixed and stained with an antibody
against G3BP and examined by fluorescence microscopy.

Both treatments

resulted in the formation of cytoplasmic puncta containing G3BP consistent with
the formation of SGs. A fraction of Syk-EGFP co-localized with G3BP-containing
bodies in cells treated with either stimulus (Fig. 5.1). Syk-EGFP also colocalized
with another SG marker, TIAR, in MCF7-BD cells treated with MG132 (Fig. 5.2A).
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Syk-EGFP also was recruited to G3BP-containing puncta in Syk-EGFPexpressing DT40 lymphoma cells treated with MG132; and endogenous Syk
colocalized with TIAR in human DG75 B lymphoma cells treated with sodium
arsenite (Fig. 5.2B and 5.3).
A redistribution of Syk within the cell following the induction of SGs also
was examined biochemically. MCF7-BD cells stably expressing Syk-EGFP were
treated with MG132 to induce SG formation. At timed intervals, cells were lysed
and separated into detergent-soluble and insoluble fractions.

Western blot

analyses demonstrated an increased level of Syk-EGFP in the detergentinsoluble fraction following the addition of MG132 (Fig. 5.4). The accumulation of
Syk-EGFP in the insoluble fraction increased at each time point over the fourhour treatment period. Increased levels of eIF2a also appeared in the insoluble
fraction as a function of treatment time.

The level of Syk-EGFP in MG132-

induced cytoplasmic puncta continued to increase over an extended 12-hour time
period as detected by fluorescence microscopy (Fig 5.5).
To further confirm a recruitment of Syk to SGs, we immunoprecipitated
G3BP from lysates of Syk-EGFP-expressing MCF7-BD cells that had been
treated with sodium arsenite to induce SG formation. The anti-G3BP immune
complexes were separated by SDS-PAGE and examined for the presence of
Syk-EGFP by Western blotting. We observed a time-dependent association of
Syk with G3BP in arsenite-treated cells (Fig. 5.6A), consistent with the two
proteins being present in the same complex.
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Similarly, we found Syk-EGFP in anti-G3BP immune complexes isolated from
lysates of cells treated with MG132 (Fig. 5.6B).

Thus, evidence from both

biochemical and fluorescence microscopy approaches indicated that Syk was
actively recruited to SGs and was particularly prevalent in SGs formed during
prolonged exposure to stress-inducing agents.

5.3 Syk is active in SGs
To determine if Syk was active when recruited to SGs, we monitored by
Western blotting Syk-dependent protein phosphorylation in cells induced to form
SGs by treatment with either sodium arsenite or MG132. For these studies, we
used a line of MCF7-BD cells in which the expression of Syk-EGFP could be
induced with tetracycline.32 Cells either treated or not treated with tetracycline
were exposed to sodium arsenite for increasing lengths of time. Western blotting
analyses of whole cell lysates with antibodies against phosphotyrosine revealed
a pronounced increase in the level of tyrosine-phosphorylated proteins
selectively in cells induced to express Syk-EGFP (Fig. 5.7). An examination of
Syk-EGFP immunoprecipitated from cells and examined by Western blot with
phosphotyrosine antibodies confirmed that Syk itself was phosphorylated on
tyrosine in cells treated with sodium arsenite (Fig. 5.8A). An increase in the
tyrosine-phosphorylation of Syk also was observed in cells treated with MG132
(Fig. 5.8B).
We next asked if the phosphorylation on tyrosine of proteins within SGs
was enhanced in cells treated with MG132. MCF7-BD cells lacking Syk or stably
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expressing Syk-EGFP were left untreated or were treated with either MG132 or
sodium arsenite, fixed, stained using antibodies against phosphotyrosine and
TIAR, and examined by confocal microscopy. There was a significant increase in
a punctate pattern of phosphotyrosine staining in cells stably expressing SykEGFP when treated with either MG132 (Fig. 5.9) or sodium arsenite (Figure
5.10). These puncta co-localized with structures containing both TIAR and SykEGFP, confirming the identification of these as SGs. This enhanced tyrosinephosphorylation was largely dependent on the expression of Syk-EGFP.

To

confirm that this phosphorylation within SGs was specifically dependent on Syk
and its catalytic activity, we compared MCF7-BD cells stably expressing SykEGFP to cells expressing an analog-sensitive form of Syk-EGFP (Syk-AQLEGFP).33 Syk-AQL is an engineered form of Syk with mutations within the ATPbinding site that make it uniquely sensitive to inhibition by analogs of PP1 that
have bulky side chains that preclude their binding to the wild-type kinase.43 Both
sets of cells were pretreated with 1-NM-PP1, a selective orthogonal inhibitor of
Syk-AQL-EGFP, and then treated with MG132 for three hours to induce SG
formation.

Cells

were

fixed

and

stained

using

antibodies

against

phosphotyrosine and TIAR (Fig. 5.11). The increase in tyrosine phosphorylation
stimulated by MG132 was largely inhibited by 1-NM-PP1 in cells expressing SykAQL-EGFP, but not in cells expressing Syk-EGFP, which is not sensitive to the
inhibitor. Thus, the enhanced phosphorylation of proteins within SGs in cells
treated with MG132 was largely dependent on the catalytic activity of Syk.
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5.4 Recruitment of Syk to SGs requires its phosphorylation
Despite the low level of SG-associated phosphotyrosine observed in cells

expressing Syk-AQL-EGFP and pretreated with 1-NM-PP1, the inhibited kinase
was still localized in SGs (Fig. 5.11). This suggested that the recruitment of Syk
to SGs or its retention there might not be dependent on its catalytic activity. To
assess this, we compared MCF7-BD cells stably expressing wild-type Syk-EGFP
to those expressing a catalytically inactive mutant, Syk-EGFP(K396R).

Both

active and catalytically inactive forms of Syk-EGFP co-localized with G3BP in
SGs when cells were treated with MG132 (Fig. 5.12). Thus, the kinase activity of
Syk was not required for its association with SG components.
When activated, Syk becomes phosphorylated on multiple residues
including tyrosines 342 and 346 (based on the murine Syk numbering system),
which are found in the linker B region that separates the tandem pair of SH2
domains from the catalytic domain.1 These residues, when phosphorylated,
serve as multi-functional docking sites that mediate interactions with several
proteins that contain SH2 domains.1,2 To assess if these tyrosines played a role
in the association of Syk with SGs, we generated MCF7-BD cells expressing
forms of Syk-EGFP in which one or both tyrosines were replaced by
phenylalanine.

Cell lines were generated that stably expressed Syk-

EGFP(Y342F/Y346F), Syk-EGFP(Y342F) or Syk-EGFP(Y346F).

These were

treated with MG132 for three hours and then fixed and stained for G3BP to mark
SGs. Unlike Syk-EGFP, Syk-EGFP(Y342F/Y346F) largely failed to localize to
SGs following treatment with MG132 (Fig. 5.13).
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Similarly, the colocalization with G3BP in SGs of both single point mutants of the
kinase was defective (Fig. 5.14). Thus, the phosphorylation of both linker B
tyrosines 342 and 346 was important for the recruitment of Syk to SGs.
Since the linker B tyrosines on Syk are phosphorylated in B cells either by
autophosphorylation or by Src-family kinases, we examined the effects of a Srcfamily kinase inhibitor on the recruitment of Syk to SGs.44 MCF7-BD cells stably
expressing Syk-EGFP were incubated with the Src-kinase inhibitor PP1 for 15
minutes prior to the induction of SG formation by the addition of MG132. We
quantified the fluorescence intensity of Syk-EGFP and G3BP in the puncta that
contained both proteins, comparing the control and PP1-treated groups. The
fluorescence intensity of Syk within SGs decreased significantly with PP1
treatment while the fluorescence intensity of G3BP within these same puncta did
not change (Fig. 5.15). These results are consistent with a contribution of Srcfamily kinases to the recruitment of Syk to SGs, likely through the
phosphorylation of Syk on Y342 and Y346.

5.5 Syk is recruited to SGs by Grb7
The requirement for two linker B tyrosines for the recruitment of Syk to
SGs suggested a role for an adaptor protein that could bind to Syk when it is
phosphorylated on both Y342 and Y346.

To identify potential adapters we

performed a yeast two-hybrid screen using as prey a human mammary gland
cDNA library and, as bait, both an active and a catalytically inactive form of Syk.
When expressed as a Syk-GAL4 DNA-binding domain fusion protein, wild-type
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Syk becomes tyrosine-phosphorylated in yeast while the catalytically inactive
mutant does not.34 Several proteins containing SH2 or functionally related
domains were identified that bound selectively to active Syk, but not to the
catalytically inactive mutant (Fig. 5.16).

These included Grb7, Grb10, Cbl-3,

Vav3, Crk, and Shc. Of these, only Grb7 had been identified previously as a
component of SGs.45 In the yeast two-hybrid screen, Grb7 bound to full-length
Syk, failed to bind to the catalytic domain of Syk or to the tandem pair of SH2
domains, but was capable of binding to a construct containing both the linker B
region plus the catalytic domain, consistent with an interaction mediated by
residues within linker B. To explore this further, we performed an in vitro pulldown assay in which the immobilized GST-SH2 domain of Grb7 was incubated
with lysates of MCF7-BD cells expressing either wild-type Syk-EGFP or SykEGFP(Y342F/Y346F).

As shown in Fig. 5.17A, the SH2 domain of Grb7

preferentially interacted with the wild-type kinase, supporting a role for Y342 and
Y346 in the association Syk with Grb7. To confirm the localization of Grb7 to
SGs, we treated MCF7-BD cells expressing Syk-EGFP with MG132 and then
stained cells with antibodies against TIAR and endogenous Grb7. Fractions of
both Syk-EGFP and Grb7 relocated into the detergent insoluble fraction of
MCF7-BD cells following their treatment with MG132 (Fig. 5.17B). In addition,
endogenous Grb7 could be co-immunoprecipitated with G3BP selectively under
conditions that promoted the formation of SGs; and this interaction did not
require the presence of Syk (Fig. 5.18).
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In contrast, the association of Syk with Grb7 did not require SG formation (Fig.
5.19). Both Syk and Grb7 proteins localized to cytoplasmic puncta that also
contained TIAR (Fig. 5.20).
To investigate further if the SH2 domain of Grb7 was involved in the
recruitment of Syk to SGs, we inactivated the domain by mutating the essential
arginine in the canonical phosphotyrosine binding site to a methionine. Wild-type
Grb7 with an mCherry tag at the C-terminus (Grb7-mCherry) and Grb7mCherry(R451M) were transiently expressed in MCF7-BD cells expressing SykEGFP, which were then treated with MG132 to induce SG formation. While wildtype Grb7-mCherry localized to SGs along with Syk-EGFP and TIAR. Neither
Grb7-mCherry(R451M) nor Syk-EGFP localized to TIAR-containing SGs (Fig.
5.21A and 5.21B).

Thus, a functional SH2 domain of Grb7 promotes the

recruitment of both Syk and Grb7 to SGs.

5.6 Syk promotes the clearance of SGs
We compared the number of SGs formed in MDF7-BD cells expressing or
lacking Syk-EGFP following a 3 hour treatment with MG132. The number of SGs
formed per cell was on average higher in Syk-deficient cells than in cells stably
expressing Syk-EGFP (Figure 5.22). This suggested a role for Syk in modulating
SG dynamics. To explore this further, we examined the effect of Syk on the
ability of cells to clear SGs following their release from the stress stimulus.
MCF7-BD cells expressing Syk-EGFP or lacking Syk were treated with MG132
for 3 hours to induce SGs. The cells were washed and allowed to recover in
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drug-free media for 4 hours. Cells were then fixed and immunostained with an
antibody against G3BP to detect SGs. The number of cells containing >3 SGs
were counted as SG positive (SG+) while those with 3 or fewer SGs were
counted as SG negative. The presence or absence of Syk in MCF7-BD cells had
little influence on the number of SG+ cells formed during the initial 3-hour
incubation.

However, far fewer Syk-EGFP-expressing cells retained SGs

following the four-hour recovery period as compared to cells lacking Syk (Fig.
5.23). To confirm this observation, we performed a biochemical assay to assess
changes in the level of phospho-eIF2 by Western blot analysis. In MCF7-BD
cells, the induction of SGs with MG132 resulted in an increase in the extent of
phosphorylation of eIF2 in both Syk-expressing and Syk-deficient cells (Fig.
5.24).

However, the level of phospho-eIF2 decreased to a greater extent

following the four-hour recovery phase in cells expressing Syk-EGFP than in
cells lacking the kinase, consistent with the presence of fewer SGs.
To assess whether the catalytic activity of Syk was necessary for SG
clearance, we compared Syk-deficient MCF7-BD cells to those stably expressing
either Syk-AQL-EGFP or Syk-EGFP. Cells were treated with MG132 for three
hours to induce SG formation and were then washed and allowed to recover in
fresh media for four hours. Where indicated, an orthogonal inhibitor of Syk-AQL,
3-MB-PP1, was added either immediately following the removal of MG132 or one
hour later (Fig. 5.25A and 5.25B).46 Cells were fixed, stained using a G3BP
antibody, and examined for the presence of SGs. As observed previously, most
cells lacking Syk retained SGs after the four hour recovery period.
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In contrast, most cells expressing either Syk-EGFP or Syk-AQL-EGFP were
largely free of visible SGs 4 hours after removal of the MG132. The addition of
3-MB-PP1 had no effect on this reduction in SGs in the Syk-EGFP-expressing
cells, but effectively blocked the clearance of SGs from cells expressing SykAQL-EGFP. When 3-MB-PP1 was added one hour after the removal of MG132,
the number of Syk-AQL-EGFP-expressing cells that were SG+ was reduced by
approximately 50%. Thus, many cells were able to clear most SGs in the first
hour following removal of MG132, but further clearance could be blocked by a
kinase inhibitor.
To determine if the association of Syk with SGs also was required for their
clearance, we compared MCF7-BD cells stably expressing Syk-EGFP to those
expressing Syk-EGFP(Y342F/Y346F), which is catalytically active, but fails to
associate with SGs. Cells again were treated with MG132 for 3 hours and then
washed and allowed to recover for 4 hours. The number of SG+ cells was much
higher for those expressing Syk-EGFP(Y342F/Y346F) as compared to those
expressing wild-type Syk-EGFP (Fig. 5.26). Thus, both the catalytic activity of
Syk and its association with SGs are required for the clearance of SGs from cells
after removal of the stress stimulus.
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5.7 SGs are cleared through autophagy
Recent data indicate that SGs can be cleared from cells through the

process of autophagy.20 To determine if autophagy was involved in the Sykdependent clearance of SGs, we treated MCF7-BD cells stably expressing SykEGFP with MG132 for 3 hours to induce SG formation. Cells were washed and
allowed to recover in the absence of MG132, but in the presence of one of two
known inhibitors of autophagy: DBeQ or 3-MA. Cells were then fixed and stained
with a G3BP antibody to detect SGs. Both autophagy inhibitors blocked the
ability of Syk-EGFP to promote SG clearance in cells recovering from MG132induced stress (Fig. 5.27).
Since cells expressing Syk-EGFP effectively cleared SGs while cells
lacking Syk did not, we compared MCF7-BD cells expressing or lacking the
kinase for the formation of autophagosomes during recovery from MG132induced stress. Cells were treated with MG132 for 3 hours, washed and allowed
to recover for 4 hours in the absence of the proteosome inhibitor. Cells were
fixed and stained for LC3, a protein that is processed and incorporated into
maturing autophagosomal membranes and thus serves as a useful marker for
these vesicles.47

Abundant LC3-positive vesicles were observed in cells

expressing Syk-EGFP as opposed to cells lacking Syk, which exhibited few
autophagosomes (Fig. 5.28). To determine if the association of Syk with SGs
also was important for autophagosome formation, we compared MCF7-BD cells
expressing Syk-EGFP to those expressing Syk-EGFP(Y342F/Y346F).

Cells

were treated with MG132 and allowed to recover as described above. Again,
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LC3-positive vesicles were much more plentiful in the Syk-EGFP-expressing
cells as compared to cells expressing Syk-EGFP(Y342F/Y346F) (Fig. 5.29).
These results indicate that the recruitment of Syk to SGs promotes their
clearance through the recruitment or formation of autophagosomes in a process
that requires the catalytic activity of the kinase.

5.8 SG clearance promotes cell survival
Since Syk functions as a pro-survival factor in numerous cancer cell types,
we asked if the expression of the kinase might alter the capacity of cells to
survive an insult that results in the formation of SGs.4 MCF7-BD cells expressing
Syk-EGFP or lacking Syk were treated with low concentrations of sodium
arsenite for 3 hours, conditions under which cells formed numerous small SGs.
Cells were washed and then allowed to recover and proliferate in fresh media for
24 hours. Cell survival/proliferation was then measured using the MTT assay.
While cells expressing Syk grew normally following removal of the stress
stimulus, the growth of cells lacking Syk was greatly attenuated (Fig. 5.29).
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5.9 Discussion
Our study supports a model in which Syk is recruited to SGs that are

induced in response to external agents that cause oxidative stress and disrupt
protein folding or interfere with the ubiquitin-proteosome system.

This

recruitment requires the phosphorylation of Syk on a pair of tyrosines in the linker
B region, which creates a docking site for the SG component, Grb7. Once at the
SG, Syk is active and catalyzes the phosphorylation of proteins on tyrosine that
promote the clearance from the cell of SGs through autophagy, thus enabling the
cells to recover from the initial stress stimulus.
The recruitment of Syk to SGs requires its phosphorylation on the two
tyrosines found within the sequence, YESPYADP. Multiple proteins have been
described that contain SH2 domains capable of binding within this region; and
many of these SH2 domains recognize Syk preferentially when both tyrosines
(Y342 and Y346) are phosphorylated.48,49 This was first demonstrated for the Cterminal SH2 domain of phospholipase PLC-g (PLCC).48

In this case,

phosphotyrosine-342 binds in the canonical phosphotyrosine binding pocket
found within all SH2 domains while phosphotyrosine-346 binds at a second site
found only in a subset of SH2 domains. Here the phosphate group interacts with
two critical lysines.

Interestingly, these two lysines are conserved in the

sequence of the Grb7. The expression of a form of Grb7 with an SH2 domain
disabled by a point mutation blocks the recruitment of Syk to the SG consistent
with an SH2 domain-mediated interaction between Syk and Grb7. Unexpectedly,
the association of Grb7 with the SG also is inhibited by this mutation.

This
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suggests that the Grb7 SH2 domain is important for both its interaction with Syk
and with SGs. This may reflect the fact that both Grb7 and its isolated SH2
domain are dimers, capable of binding simultaneously more than one ligand.50,51
The site or sites on the SG to which the Grb7 SH2 domain binds is not known,
nor is it known whether or not this site contains phosphotyrosine as the Grb7
SH2 domain is capable also of recognizing amino acid sequences that lack a
phosphoamino acid.52,53
The ability of a catalytically inactive form of Syk to associate with SGs
suggests that the phosphorylation of Y342 and Y346 can be catalyzed by
kinases other than Syk itself. This is consistent with previous phosphopeptide
mapping experiments demonstrating the phosphorylation of catalytically inactive
Syk on Y342 and Y346 in B cells activated through the antigen receptor in a
manner dependent on the expression of Lyn, a Src-family kinase.44 Consistent
with this idea, the inclusion of a Src-kinase inhibitor reduced the content of Syk in
SGs. Interestingly, Src kinases also are known to phosphorylate at least one
other SG component, Sam68/KHDR1.10,54
We find that the presence of Syk in MCF7 cells is not required for the
formation of SGs. In fact, the number of SGs present in Syk-expressing cells
treated for 3 hours with MG132 is reduced compared to the number in cells
lacking the kinase. The presence or absence of Syk, however, does have a
dramatic effect on the disappearance of SGs from cells once the stress is
removed. This clearance of SGs requires the association of Syk with the SG, as
Syk-EGFP(Y342F/Y346F) fails to promote SG clearance. The addition of an
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inhibitor orthogonal to Syk-AQL-EGFP to cells expressing Syk-AQL-EGFP, but
not to cells expressing Syk-EGFP, also blocks SG clearance. This indicates an
essential and specific role for Syk-catalyzed tyrosine phosphorylation in this
process.

Visualization

of

protein-tyrosine

phosphorylation

by

immunofluorescence clearly demonstrates a substantial increase in the
phosphorylation of proteins resident in or near SGs. This phosphorylation is
largely Syk-dependent as it is selectively blocked in cells expressing Syk-AQLEGFP upon treatment with the Syk-AQL-specific inhibitor. However, the exact
protein or proteins that Syk phosphorylates to promote SG clearance remains to
be determined.
SGs are thought to disassemble following the removal of stress, allowing
sequestered mRNAs to return to ribosomes for translation.11 A recent genetic
screen in yeast, however, clearly indicates a critical role for components of the
autophagy pathway in modulating the dynamics of SG removal.20 Consistent with
a role for autophagy in SG dynamics in MCF7 cells, the addition of inhibitors of
autophagy clearly blocks the Syk-dependent clearance of SGs in cells following
removal of the stress stimulus.

Also consistent with this mechanism, a

substantial increase in LC3-positive vesicles is seen in cells recovering from
stress when cells contain a catalytically active form of Syk that also is capable of
binding to SGs. These observations clearly implicate Syk as an important factor
in regulating the removal from cells of SGs through autophagy. Grb7, which
promotes SG formation or enhances SG stability, has been reported also to
recruit to SGs focal adhesion kinase (FAK), which phosphorylates G4b7 to
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promote SG disassembly.45 It is not known if autophagy contributes to the loss of
SGs that is seen following the recruitment of FAK and phosphorylation of Grb7.
The consequences of the presence or absence of Syk in tumor cells are
manifested in different ways depending on the tumor cell type and its stage of
development.4 In many tumors, the expression of Syk enhances cell survival,
especially in the face of external or internal factors including oxidative stress,
exposure to chemotherapeutic agents, expression of oncogenes like activated KRas or loss of Rb.4,5,8,9 Multiple mechanisms have been described to account for
many of Syk’s protective effects on cells including activation of the PI3K/Akt prosurvival pathway leading to the stabilization of the anti-apoptotic proteins Mcl-1
and/or XIAP, activation of mTOR, activation of STAT3 or STAT5, enhanced
transcription of NF-kB-regulated genes, and stabilization of the mRNA for Bcl-xL
through an association of Syk with nucleolin.8,9,55-61

The contributions of

autophagy to cancer cell survival also are context dependent. While a lack of
autophagy can contribute to tumorigenesis in some cancer types, in some
established tumor cells autophagy instead confers a survival advantage that is
particularly important for the cancer cell resistance to external stresses including
hypoxia and exposure to radiation or chemotherapeutic agents.24-27 Thus, many
established tumors rely on autophagy as a mechanism to survive elevated
metabolic or therapeutic stress; and inhibitors of autophagy can sensitize some
tumors to the actions of chemotherapeutic agents.26 MCF7 cells are relatively
insensitive to the inhibition of autophagy for basal cell growth.62 However, we
find that MCF7 cells expressing Syk are better able to recover from exposure to
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sodium arsenite, which induces SG formation, than are cells lacking the kinase.
This suggests that the increased autophagy promoted by the presence of Syk
facilitates cell survival in response to stress. Thus, Syk-dependent enhancement
of autophagy provides an additional mechanism by which the kinase can enable
cancer cells to evade stress-induced cell death. This suggests that Syk inhibitors
would be useful in sensitizing a subset of Syk-expressing cancer cells to the
actions of chemotherapeutic agents.
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CHAPTER 6. FUTURE DIRECTIONS

6.1 Introduction
Future studies could be directed toward exploring the molecular
mechanisms by which Syk modulates cytoskeletal networks and determining how
Syk regulates autophagy. Several questions could be addressed including 1)
how Syk-dependent phosphorylation of other microtubule-associated proteins
affects cytoskeletal properties and 2) how Syk regulates aggresome and stress
granule clearance through autophagy.

6.2 Syk-dependent phosphorylation of MAPs and cytoskeletal properties
For microtubules to maintain their dynamic functions, they rely on a variety
of microtubule-stabilizing proteins and other microtubule-associated proteins.
Interestingly, a number of microtubule-associated proteins were identified in our
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mass spectrometry analyses of Syk substrates.1-3 Among these were EB1,
MAP1B, and FOP, which were all identified as being phosphorylated in a Sykdependent manner. We observed that Syk functions through MAP1B to promote
microtubule stability; however, this change in stability was not entirely due to
MAP1B.4 MDA-MB-231 cells treated with shRNA to knockdown MAP1B were
less stiff and more elastic compared to cells that expressed endogenous MAP1B.
However, the MDA-MB-231 cells with reduced MAP1B were still more stiff and
less elastic than the cells lacking endogenous Syk.4 This suggests that other
microtubule-associated proteins help to regulate microtubule stability in a Sykdependent manner even when MAP1B protein is absent. Alternatively, Syk may
regulate other cytoskeletal networks like actin polymers to stabilize microtubules
in conjunction with MAP1B.
The EB1-protein family includes EB1, RP1, and EBF3. EB1, like other
family members, localizes to microtubule tips and has been used as a marker for
microtubule ends and to track microtubule dynamics. 5 It also has been shown to
interact with the dynactin complex, which activates dynein motor proteins
associated with microtubules.6 EB1 has been shown to have an important role in
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cell polarity maintenance by its association with microtubules and through linking
this association to actin protrusion, thus facilitating the cross-talk between these
cytoskeletal networks.7

It is hypothesized that PKC- phosphorylates EB1 and

that this phosphorylation aids EB1’s contribution to cellular polarity.7 EB1 also
has been shown to localize on astral microtubules, and enhance their stability.7 I
performed a shRNA knockdown targeting EB1 protein in MDA-MB-231 cells
stably expressing Syk-EGFP.

However, I observed that Syk still stabilized

microtubules when cells were treated with nocodazole even in the absence of
EB1. Thus, it appeared that in MDA-MB-231 cells, EB1 was not responsible for
Syk’s ability to stabilize microtubules
FGFR1 oncogene partner (FOP) was first discovered as a fusion partner
of FGFR1 that occurred by a t(6;8) translocation in stem cell myeloproliferative
disorders.8 The chimeric protein localized to the centrosome where the FGFR1
kinase domain initiated phosphorylations that led to deregulation of the cell
cycle.8-10 The normal role of FOP is to anchor microtubules to the centrosome.11
Its interaction with CAP350 maintains its association with the centrosome. In
addition, FOP is required for the recruitment of EB1 protein to the centrosome.11
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I generated MDA-MB-231 cell line with knockdown of FOP using a lentiviral
shRNA delivery system that targeted FOP. Cells in which FOP protein was
knocked down had a less dense microtubule network emanating from the
centrosome as compared to cells expressing endogenous FOP protein,
consistent with a role for FOP in anchoring microtubules to the centrosome.
Interestingly, the treatment of FOP-knockdown cells with nocodazole resulted in
a pronounced blebbing phenotype that was enhanced in cells expressing Syk.
This blebbing was inhibited by a ROCK (Rho-associated protein kinase) inhibitor
suggesting a role for Syk also in modulating actin-myosin dynamics. It would be
interesting to investigate further the pathways through which Syk modulates the
properties of the actin cytoskeleton in cancer cells.
Cellular blebbing is one mechanism of motility. In 2003, it was shown that
cancer cells that invade through a 3D collagen matrix under conditions in which
matrix degradation is blocked do so through an amoeboid mode of invasion
involving the formation of bleb-like constriction rings.12 It appears that cancer
cells use this amoeboid mode of invasion to bypass the requirement for
extracellular matrix proteolysis as an alternative way to metastasize.12 Cellular
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blebbing has been identified in many cancer cell lines including melanoma and Tcell lymphoblastic leukemia.13-14

The mechanisms that promote blebbing are

ROCK dependent. Intra or extracellular signals can initiate the conversion of
RhoA-GDP to RhoA-GTP, and this results in the formation of a ROCK1, 3phosphoinositide-dependent protein kinase (PDK1), and RhoA-GTP complex.
ROCK1 phosphorylates myosin light chain (MLC) phosphatase and promotes
acto-myosin contractility leading to blebbing. Deficiencies in the actin-binding
proteins filamin A and talin have been shown to induce blebbling,15 but depletion
of FOP and its effects on cellular blebbing have not been investigated.
Further investigations into how Syk influences FOP-dependent blebbing
through the ROCK pathway would be of interest. Future studies could evaluate
whether Syk-dependent phosphorylation sites on FOP affect its ability to anchor
microtubules to the centrosome or form complexes with CEP350 and/or EB1,
and determine whether or not phosphorylation influences blebbing.

Motility

assays could also be performed using 3D cultures to investigate if these blebs
promote invasion. Biochemical analyses could also be performed to investigate
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whether RhoA activation and MLC phosphorylation occur in cell lines where FOP
protein expression is reduced.

6.3 How does Syk regulate aggresomes and stress granule clearance through
autophagy and the cytoskeleton
Autophagy has been shown to be important in clearing protein aggregates
accumulated in both stress granules and aggresomes. Aggresomes are
aggregated puncta of misfolded proteins.16

We have identified that, under

various stress conditions, Syk can either localize to stress granules and
potentially also with aggresomes.

We have identified a number of proteins

through mass spectrometry analyses that are involved in the export of misfolded
proteins from the ER to the cytoplasm including valosin-containing protein (VCP),
valosin-containing protein (P97)/P47 complex interacting protein 1 (VCPIP1), Nethylmaleimide-sensitive factor and valosin-containg protein (NSFL1C), ubiquitin
fusion degradation protein 1 homolog (UFD1L), and nuclear protein localization 4
homolog (NPLOC4).

Interestingly, VCP has been shown to be critical for

autophagy and can impair the formation and clearance of stress granules and the
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clearance of protein aggregates.17,18 Stress granule clearance is important to
maintain cellular homeostasis especially since the accumulation of protein
aggregates can lead to neurodegenerative disease. Lou Gehrig’s disease (ALS)
is a motor neuron degenerative disease. One of the pathological hallmarks in
this disease is the presence of puncta containing TAR DNA-binding protein 43
(TDP-43), which is a protein that colocalizes with stress granules in degenerating
neurons.19 VCP has been shown to form a complex with VCPIP1, UFD1L, and
NPLOC420 and mutations in VCP are known to cause familial ALS.21 Therefore, I
hypothesize that the clearance of stress granules and aggresomes by autophagy
could be regulated through the phosphorylation of these factors and thus
modulation of complex formation and/or function.

First, to test whether

endogenous VCP interacts with the Syk complex, immunoprecipitation of VCP
followed by a Western blot using antibodies for Syk could be performed. Next, if
these two proteins are in a complex together, then various phosphorylation site
mutants of VCP could be expressed in cells stably expressing Syk to evaluate
whether phosphorylation of VCP modulates complex formation and autophagy.
Ultimately knockdown studies using shRNAs targeting UFD1L and NPLOC4
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could be performed to evaluate if either of these proteins are critical components
required for the clearance by autophagy of either stress granules or aggresomes.
Furthermore, EB1 has been linked to the absent melanoma 2 protein (AIM2)
complex involved in inflammasome formation and is required for autophagydependent secretion of IL1-.22 It would be interesting to determine if EB1 is an
important participant in the process by with stress granules or aggresomes are
cleared from cells by autophagy.
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